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AMD Age-related macular degeneration 
AMPK  AMP-activated protein kinase 
ATP Adenosine triphosphate 
BAT Brown adipose tissue 
BMI Body mass index 
BrdU  5-Bromo-2’-deoxyuridine 
cAMP cyclic-adenosine monophosphate 
CDK Cyclin-dependent kinase 
CYP  Cytochrome  
DCFDA 2’,7’ – dichlorofluorescin diacetate 
DEX Dexamethasone 
DMEM Dulbecco´s modified Eagle´s medium 
ELISA  Enzyme-linked immunosorbent assay 
FBS  Fetal bovine serum 
FDR  False discovery rate 
GC Glucocorticoids 
GSEA  Gene Set Enrichment Analysis 
H2O2  Hydrogen peroxide 
IBMX 3-isobutyl-1-methylxanthin  
IQR  Interquartile range 
IR Infrared 
KEGG  Kyoto Encyclopedia of Genes and Genomes 
LED  Light-emitting diode 
LLLT  Low-level laser (light) therapy 
MCE Mitotic clonal expansion 
NAALT  North American Association for Light Therapy 
NES  Normalized Enrichment Score 
NF-κB  Nuclear factor kappa B 
NIR  Near-infrared 
PBM Photobiomodulation 
PBS  Phosphate buffered saline 
RIN  RNA integrity number 
  
 
ROS  Reactive oxygen species 
scWAT sub cutaneous white adipose tissue 
SD  Standard deviation 
TNF  Tumor necrosis factor 
UV  Ultraviolet 
VIS  Visible 
WALT  World Association for Laser Therapy 
WAT White adipose tissue 
WHO World Health Organization  
XTT  Sodium 3’-[1-(phenylaminocarbonyl)-3, 4-
tetrazolium] bis (4-methoxy-6-nitro) benzene 
sulfonic acid hydrate 
ΔΨm  Mitochondrial membrane potential 
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1. Introduction 
1.1 Photobiomodulation: definition and history 
Since ancient times light has been used for therapeutic purposes first using sunlight and then 
electric lamps discovered around the 19th century by Davy (arc lamp) and Edison 
(incandescent bulb). The growing interest in laser technology led Niels Finsen to win in 1903 
the Nobel Prize for physiology and medicine for his work on the treatment of skin 
tuberculosis with concentrated UV rays and smallpox with red light
1
. A new scientific branch, 
recognized for years under the name of low level laser therapy (LLLT), is born. However, the 
universally recognized father of LLLT is the Hungarian doctor Endre Mester who in the early 
60's, using a ruby laser (wavelength 694.3 nm), began testing in animal models, mainly on the 
skin of rats, with the aim of assessing the presence of a carcinogenic effect of low energy 
density laser (1 J/cm2). After the first observations, no detecting differences in the 
carcinogenic sense between treated and untreated animals, he began to carry out studies on the 
effect of laser therapy in healing processes, investigating in vivo tissue repair in burns and 
traumas, and in vitro phagocytosis of bacteria by leukocytes, hemoglobin synthesis and 
healing of ulcerative lesions not responding to conventional therapies
2, 3
. The difficulty in 
defining such a vast field of application can be seen in the large number of definitions in the 
international scientific literature, where the term LLLT is accompanied by numerous 
synonyms such as "photobiomodulation", "phototherapy", "photomedicine", 
"photoirradiation", "biomodulation" and "biostimulation"
4
. Only in 2014 The North American 
Association of Laser Therapy (NAALT) and the World Association of Laser Therapy 
(WALT) reached a consensus on the nomenclature introducing the term 
“photobiomodulation” (PBM) which defines a form of light therapy that utilizes non-ionizing 
light sources, including lasers, light emitting diodes (LEDs), and/or broadband light, in the 
visible (400 – 700 nm) and near-infrared (700 – 1100 nm) electromagnetic spectrum. It is a 
non-thermal process involving endogenous chromophores eliciting photophysical (i.e., linear 
and nonlinear) and photochemical events at various biological scales. This process results in 
beneficial therapeutic outcomes including, but not limited, to the alleviation of pain or 
inflammation, immunomodulation, and promotion of wound healing and tissue regeneration
4-
5
. 
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1.1.1 Irradiation parameters 
The lack of knowledge of the molecular effects of PBM and a poor understanding of the 
radiometric parameters which influence the repeatability and reliability of the practical 
application of PBM is still the subject of controversy
6
. The studies that provided indications 
for the reporting of radiometric parameters indicated a maximum of ten key radiometric 
parameters such as: wavelength, power density, irradiation time, beam area, energy density, 
radiant exposure, pulse parameters, number of treatments, interval between treatments and 
anatomical location
7
. 
Especially the power density or irradiance [W/cm
2
] and the energy density or fluence [J/cm
2
] , 
are fundamental to make different studies comparable
6
. In fact, it is the combination of these 
two parameters that determines the characteristics of biomodulation. Too low dosages may 
not have any effect, too high ones may have an inhibitory effect. This biphasic response 
follows the Arndt Schultz
8, 9
 law according to which weak stimuli slightly accelerate vital 
activity, stronger stimuli increase it until the maximum peak beyond which such activity is 
suppressed with inhibitory effects
10,11
 (Figure 1).  
 
Figure 1: Biphasic dose response in LLLT. Three dimensional surface plot illustrating the effects of an 
increasing irradiance [W/cm
2
] or irradiation time [s] on dose-dependent PBM resulting in stimulation or 
inhibition.
12
 
 
Biostimulation therefore seems to require fluences between 0.05 J/cm
2
 and 10 J/cm
2
 for a 
positive response while above 10 J/cm
2
 are related to bioinhibition
13
. 
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1.1.2 Mechanisms of action 
By convention, the PBM action mechanisms can be divided into primary and secondary 
mechanisms. According to the first "law of photochemistry", the primary mechanisms are 
dependent on the absorption of light by photo-acceptor systems (chromophores). Cytochrome 
C oxidase, opsins, flavins and flavoproteins and porphyrins are proposed as the main 
photoacceptors able to mediate a biological response in PBM
14, 15
. 
Karu et al.
16
 have postulated four primary mechanisms of action that can modulate biological 
activity: 1) alteration of the redox state and acceleration of electron transport 2) changes in 
biological activity due to increase in local temperature of absorbent chromophores 3) one-
electron autooxidation and O2
.-
 production (and subsequent production of H2O2) 4) 
photodynamic action and O2 production. (Figure 2). These primary light-induced mechanisms 
of action are followed by biochemical cascade reactions in the cells that do not require further 
stimulation and occur in the dark (secondary mechanisms). This signal transduction is related 
to changes in the parameters of cellular homeostasis. However, the crucial step seems to be an 
alteration of the redox state: a shift towards oxidation is associated with stimulation of cell 
viability while a shift towards reduction is linked to inhibition. 
 
 
Figure 2: Possible primary reactions with a photo-acceptor molecules after promotion to excited electronic 
states
16
.
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1.1.3 Medical applications: PBM for fat reduction and body contouring 
The photochemical reactions underlying PBM can define several clinical effects: the 
promotion of wound healing, the anti-inflammatory action, the analgesic effect and a 
treatment for other neurological problems (Figure 3)
12,17,18
. 
 
 
Figure 3: Illustration of physiological effects of LLLT
19
.
 
In addition to the already common clinical applications in the last decade LLLT/PBM has also 
been investigated as an adjuvant in liposuction
20-23
, cellulite reduction, non-invasive body 
contouring
24-26
 and improvement of blood lipid levels
27
. However, further studies are 
necessary to clarify the mechanisms of action underlying this new fat reduction procedure. 
For first was proven as effect of LLLT on adipocytes the formation of transient micropores on 
the cell membrane and consequent the release of intracellular lipids
22
. Another mechanism of 
action proposed seems to be the activation of the complement cascade that can cause 
adipocyte apoptosis and subsequent release of lipids
28
. It is also possible that LLLT/PBM can 
stimulate the mitochondria in the adipocytes with an increase in ATP levels followed by an up 
regulation of cAMP and activation of protein kinases. The final effect is the stimulation of 
cytoplasmic lipase for the conversion of triglycerides into fatty acids and glycerol
29,30
.To date, 
all proposed LLLT studies use wavelengths in the red and infrared spectrum. No studies 
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concerning fat reduction and body contouring have been carried out with shorter wavelengths 
such as blue light. 
 
1.2 Blue light 
Most of the studies underpin the application of PBM using wavelengths between 600–1100 
nm. Wavelengths <600 nm are less investigated or detailed. The utilization of blue light (400–
500 nm) especially is moreover encompassed by critical discussion identifying with the 
reason that the edge between “safe” blue light and "harmful ultraviolet (UV) light" is not well 
characterized. (Figure 4). The fact of high photon energy makes blue light able to prompt 
photochemical damage inducing development of reactive oxygen species (ROS) and 
prompting degenerative eye ailments, for example, age-related macular degeneration 
(AMD)
31
. On the other hand blue light significantly exerts on the skin many positive attested 
effects such as antimicrobial (both bacteriostatic and bactericidal)
32
 or anti-inflammatory 
(treatment of skin lesion as psoriasis and acne)
33
. 
 
 
Figure 4: Electromagnetic spectrum. Distinction between the different wavelengths in the blue spectrum 
according to their more or less harmful effects
34
.
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To date, compared to other wavelengths as red or NIR light, blue light is still limited in use. 
An added key caveat regarding the lower penetration depth is corresponding to an intensity 
decrease by 1/e (approximately 63%) at 1mm through tissue compared up to 5mm of NIR 
light. Secondly the mechanisms through which light can trigger the activation of transcription 
factors are unknown, except, as mentioned above, that ROS are proposed as mediators. The 
increased amount of ROS in cells exposed to light is presumably the result of excitation of 
endogenous photosensitizers by absorption of specific wavelengths. Notwithstanding, 
potential biomolecular targets of blue light are generally uncommon. The best candidates 
include photosensitizers concentrated in the mitochondria, such as porphyrin ring structures 
(absorption peaks at 410 - 440 nm) and flavins (absorption peaks at 450 nm)
35-37
. 
Since mitochondrial function is critical for cell survival, and mitochondria are a major 
endogenous source of ROS in cells, it has been hypothesized that blue light triggers sufficient 
redox-related stress to cause differential cell responses
38
. Limited and contrasting results on 
blue light induced signaling have been reported. Some investigations have shown a regulation 
of proliferation and differentiation or a modulation of inflammatory parameters, others growth 
inhibition and apoptosis in a cell-type-dependent manner
39-41
 
42
. It is clear that further studies 
concerning molecular and cellular mechanisms are needed to strengthen the use of blue light 
in clinical applications. 
 
1.3 Obesity and Adipocytes  
Obesity is a condition characterized by excessive accumulation of subcutaneous and visceral 
adipose tissue
43
, mainly due to a prolonged imbalance between energy intake and expenditure, 
with a body mass index (BMI) >30. The World Health Organization (WHO) has recently 
defined obesity as a "global epidemic" since over a third of the world population today is 
affected. If secular trends continue, by 2030 an estimated 38% of the world’s adult population 
will be overweight and another 20% will be obese
44
. In parallel with the increase in the 
incidence of obesity and the progression of obese individuals towards higher and higher BMI 
values, there is an increased risk of comorbidity phenomena such as diabetes mellitus type II, 
glucose intolerance, insulin resistance, hyperlipidemia and hypertension with an increase in 
cardiovascular risk, with an exponential curve that describes the correlation between BMI and 
mortality from cardiovascular events
45
. The studies carried out so far have, in fact, led to the 
conclusion that the most common forms of obesity have, probably, a multifactorial etiology
46, 
47
 that results from a complex interaction between the biology of energy metabolism and the 
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environment, passing through a possible genetic predisposition, but also hormonal, metabolic 
and behavioral aspects, such as sedentariness and high-calorie diet
48, 49
, are involved. Since a 
subversion of these lifestyles is rather unlikely, due to precise well-established socio-
economic models, due to the serious metabolic dysfunctions linked to the excessive formation 
of adipose tissue, in recent years there has been a strong increase in scientific interest aimed at 
understanding the molecular pathways that regulate the energy metabolism in humans, in 
order to identify new strategies for prevention and treatment
50, 51
. 
Interest in the biology of adipose tissue has increased substantially. To date this tissue is no 
longer considered to be an inert tissue that just stores fat
52
 but is defined a metabolically 
dynamic organ that is the primary site of storage for excess energy but it serves as an 
endocrine organ capable of synthesizing a number of biologically active compounds that 
regulate metabolic homeostasis
53
. 
In mammals adipose tissues can be of two types with distinguishing properties: white adipose 
tissue (WAT) and brown adipose tissue (BAT)
54
. The adipocyte of WAT contains a large, 
single lipid droplet that occupies the most of cell volume, pressing the nucleus and cytoplasm 
to the cell periphery (unilocular adipocyte) (Figure 5). WAT is responsible for many 
functions, such as synthesis of triglycerides and storage as energy reserve (1Kg = about 7000 
Cal); hydrolyzation of the deposited triglycerides and release of free fatty acids into the 
bloodstream; synthesis of triglycerides from glucose; mechanical shock absorber, thermal 
insulation and producer of hormones and biologically active substances (adipokines), 
including leptin, adiponectin, interleukin 6 (IL-6) and tumor necrosis factor-α. BAT contains 
high mitochondrial content and multiple lipid droplets (multilocular adipocyte), and are 
derived from distinct highly vascular and innervated adipose tissue depots
44
. The main 
function of brown adipose tissue is to produce heat. The thermogenic activity of brown 
adipose tissue is also induced by excessive calories, in an attempt to dissipate unnecessary 
energy by avoiding excessive accumulation of fat. Essential for newborns it is scarcely 
present in adults. 
Introduction 
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Figure 5: Micro anatomy of subcutaneous white adipose tissue. In each adipocyte nucleus is surrounded 
by one (unilocular)  lipid droplet
55
.
 
 
The composition of adipose tissue is not homogeneous. The two-third are composed of the 
stroma-vascular fraction, comprising blood cells, endothelial cells, pericytes and 
preadipocytes cells and only one-third is represented by mature adipocytes.  
The increase of the adipose tissue can occur in two ways: hyperplasia, with an increase in the 
number of adipocytes, or hypertrophy, with an increase in the lipid content and volume of 
each adipocyte
56, 57
. Until a few years ago, it was believed that adipocyte hyperplasia only 
occurred in the last semester of gestation, in the first year of life and in childhood. Today, 
however, we know that this phenomenon can also occur in adults, especially when we move 
from a condition of moderate overweight to that of severe obesity. There is in fact a limit 
beyond which the adipocytes cannot further increase in volume (maximum volume=1µg). In 
this situation a further increase in fat reserves can only be achieved by increasing the number 
of adipocytes. This phenomenon was confirmed by the discovery of preadipocytes, 
undifferentiated cells immersed in the adipose tissue of adult subjects. These cells retain the 
ability to divide and, if stimulated and activated, are able to give rise to new adipocytes
58
. 
Once formed, these new adipose cells will remain so forever in that state and may therefore 
increase or decrease in volume but not in number. 
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1.3.1 Optical properties of adipose tissue 
Due the deeper subcutaneous position adipose tissue is not used to experience light exposure. 
However, a small percentage of the light can reach the hypodermis. To date a knowledge of 
the optical characteristics of adipose tissue is necessary for the development of various 
treatment methods in cosmetology and in photodynamic therapy of dermatological and 
oncological diseases
59
. The optical penetration not only depends on the wavelength of light 
but also on tissue structure, thickness and its vascularization. Despite numerous investigations 
in the field of optics of biological tissues, the optical parameters of subcutaneous adipose 
tissue in a wide spectrum remain poorly unknown. 
Studies conducted in the range 400–2500 nm on subcutaneous adipose tissue have shown the 
shape of the spectra in the visible and non-visible. In the visible spectrum the major peak is 
determined by the absorption bands of blood hemoglobin localized in the capillary vessels of 
the adipose tissue while in the IR spectral range, the shape of the reflection and transmission 
spectra is determined by the absorption bands of water, lipids, and proteins of the tissue 
matrix. In both the visible and the IR spectral ranges, the role of the main scattering structures 
is played by spherical droplets of lipids (mainly, triglycerides), which are uniformly 
distributed within the adipose tissue
60
. 
 
1.4 Adipocyte differentiation by pre-adipocyte cell line: 3T3-L1 
As model of in vitro adipose tissue, 3T3-L1 cell line, derived from 3T3 cells, is widely used 
in biological research. 3T3-L1 cells have a fibroblast-like morphology, but, under appropriate 
conditions, they differentiate into an adipocyte-like phenotype. During the differentiation 
process, biochemical and morphological characteristics of adipocyte differentiation are 
shown. Indeed, 3T3-L1 cells increase the synthesis of triglycerides and acquire the behaviour 
of adipose cells. In particular, triglycerides accumulate in lipid droplets (LDs) embedded in 
the cytoplasm.  
There are two important features of preadipocyte cell lines which make them eligible 
candidates for adipocyte differentiation study. First, it is a uniform cellular population in a 
similar differentiation stage allowing clonal cells to show a homogeneous response to the 
treatments. Secondly, the preadipocytes can be indefinitely passaged without suffering genetic 
mutation or functionality change, which provides a consistent source of cells for study of 
adipocyte differentiation
58
. Once preadipocyte cells reach confluence, growth arrest occurs. 
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After that cells can re-enter the cell cycle and, before differentiation, undergo mitotic clonal 
expansion (MCE) that consists of one or two rounds of cell division
61
. Whether MCE is 
required for differentiation is controversial
62
; however, it is clear that some of the checkpoint 
proteins for mitosis also regulate aspects of adipogenesis.  
Using a defined adipogenic cocktail, confluent preadipocytes/3T3-L1 can be differentiated 
synchronously. Maximum differentiation can be achieved by increasing intracellular levels of 
cAMP (cyclic-adenosine monophosphate) by inducing cells in the initial phase (48 hours), in 
the presence of fetal bovine serum and a hormonal cocktail consisting of insulin, 3-isobutyl-1-
methylxanthin (IBMX) and dexamethasone (DEX). 3T3-L1 can be differentiated and 
converted into mature adipocyte cells, with changes in morphology and expression of specific 
adipocyte genes. Dexamethasone is a synthetic glucocorticoid agonist (GC) that stimulates the 
GC receptor. After the first 48 hours, the insulin itself can continue the differentiation 
process. Surprisingly, DEX shows an anti-adipogenic effect at the later stage of the 
differentiation process (adipose maturation), while it has a powerful induction effect on 
adipogenesis at the early stages of differentiation, indicating the short time window of 
hormonal effects
63
. 
Thus, adipogenesis, is an ordered multistep process requiring the sequential activation of 
several groups of transcription factors, including CCAAT/enhancer-binding protein (C/EBP) 
gene family and peroxisome proliferator activated receptor-γ (PPAR-γ) which regulates 
glucose metabolism and fatty acid storage of cells
64
. In the first stage after induction, a 
signaling cascade is activated. C/EBP-β is expressed within 2-4 hours after hormonal 
induction. At this time C/EBP-β is unable to bind DNA and thus cannot play the role of a 
transcriptional activator. This function is acquired later in the differentiation program around 
14h reaching a maximum at 24h after induction. Having acquired DNA-binding function, 
C/EBP-β transcriptionally activates both PPAR-γ and C/EBP-α. Because PPAR-γ and C/EBP-
α are both antimitotic, they seem to function as terminators of MCE. The activation of these 
factors leads to the expression of many adipocyte genes and an irreversible differentiation 
process that end with the formation of a mature adipocyte phenotype
65, 66
. 
 
1.4.1 Factors affecting adipocyte differentiation 
Adipocyte differentiation can be affected in a positive or negative way by many hormones, 
growth factors, cytokines, and pharmacological compounds and so on. Adipogenic factors 
like insulin, insulin-like growth factor-1 (IGF-1), glucocorticoids, mineralocorticoids, growth 
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hormone and PPAR-γ agonists promote differentiation. Other growth factors like EGF or 
TNF and cytokines, as interleukin-11 have inhibitory effects, sometimes in a dose-dependent 
manner
67, 68
. 
Epigenetic factors
69
, miRNAs
70
 , some clock genes
71, 72
, especially Bmall and Rev-ErbA may 
play a role in adipocyte differentiation and lipogenesis. Also cell culture conditions can affect 
these processes. In fact, culturing 3T3-L1 cells in different culture dishes showed differences 
in adipocyte differentiation.
73
 
 
1.5 Aim of the study 
The rapid spread of PBM, especially for medical applications, has led to the emergence of 
numerous studies both in vivo and in vitro, most of them conducted with red or infrared light. 
This choice is due to the advantages in the application of these wavelengths, such as the deep 
penetration and the more elucidated mechanisms of action. On the other hand, still 
controversial and uncharacterized are the treatment approaches regarding blue light that, 
although considered a "bad light" for its dysregulating effects on the eyesight and circadian 
rhythm, has shown some beneficial effects for the treatment of skin diseases, such as acne and 
psoriasis. In addition, in defense of the beneficial potential of blue light, some recent studies 
have shown that exposure to sunlight can have positive effects on body weight reduction. The 
38.9% of the sun’s energy reaching exposed skin is in the visible wavelength range. In spite 
of the fact that most of sunlight in the visible spectrum does not pass through the skin, 
approximately 1–5% of blue/green light is able to penetrate through human skin to varying 
depths proportional to increasing wavelength and intensity and reach the underlying 
subcutaneous white adipose tissue (scWAT) modulating some functions such as lipid storage. 
These findings may lead to light-based treatments for obesity and other related conditions like 
diabetes.  
In order to understand and broaden the knowledge of the mechanisms of action induced by 
the exposure of blue light, this study is intended to position itself in the vast panorama of 
scientific research with the aim to assess the potential of only VIS blue light in an in vitro 
model of 3T3-L1 cells, to study mechanisms governing adipose tissue development. Given 
the inhibitory effects of using high doses of irradiation, the 21.6 J/cm
2
 and 43.2 J/cm
2
 doses 
were chosen in this project in order to modulate the adipocyte differentiation or to induce 
leakage of intracellular lipids. The effects were studied during and after the differentiation 
process, for evaluating metabolic-functional adaptations that can be divided into:  
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-Cellular response to stress damage.  
-Cellular adaptations of growth and differentiation 
-Increasing or decreasing of metabolism.  
-Regulation of gene expression profiles 
Material and Methods 
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2 Material and methods 
2.1 Cell culture 
3T3-L1 cells (ATCC
®
 CL-173
™
) (Figure 6) were cultured under standard conditions in 
humidified atmosphere at 37°C and 5% CO2. Cells were cultured in Dulbecco´s modified 
Eagle´s medium (DMEM) high glucose containing completed with 10% fetal bovine serum 
(FBS), sodium pyruvate and 1% penicillin/streptomycin (Gibco® by life technologies TM 
AG (Carlsbad/USA)) The cells were sub-cultivated before culture became 70 to 80% 
confluent and re-seeded according to the instructions of ATCC keeping a density of 2000-
3000 cell/cm
2
. For cell detachment, 0.25% Trypsin-EDTA phenol red (Gibco®) was added in 
the flask for 5 minutes at 37° and 5% CO2. Viable cells, determined by Trypan Blue 
exclusion, were quantified with a Luna
TM
 automatic cell counter and seeded in new flask for 
subculture. Irradiation treatments and all experiments described in the following sections have 
been performed into black 96-well plates to avoid light scattering and crosstalk between 
single wells. 
 
Figure 6: Low and high density 3T3-L1 cells (ATCC
®
 CL-173
™
). 
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2.1.1 Differentiation of 3T3 L1 Cell  
3T3-L1 is a type of fibroblast cells derived from mouse that differentiates into adipocytes 
under appropriate condition. The differentiation of 3T3-L1 towards adipocytes involves 
processes such as confluent culture, growth arrest, hormonal induction, and adipocyte 
differentiation. Usually after the 3T3-L1 cells become confluent, growth arrest occurs and in 
presence of hormone like insulin, cells reenter to the cell cycle and several rounds of post 
confluent mitosis (Mitotic Clonal Expansion) takes place. Hormonal inductors are provided to 
the cells through an adipogenic cocktail containing Insulin, 3-Isobutyl-1-methylxanthin 
(IBMX), Dexamethasone (DEX) in presence of FBS. Later on IBMX and DEX are removed 
from the cocktail because DEX shows anti adipogenic effects at the late stages of adipocyte 
maturation. The differentiation is performed following an established protocol (Figure 7). 
To observe adipocyte differentiation under the influence of inducers, cells were seeded in 96-
well black plates at an initial concentration of 1200 cells/well in standard culture medium. 
After 48 hours preadipocytes reached confluence and the standard culture medium was 
changed with a differentiation medium containing 89% DMEM, 10% FBS, 1% P/S, 0.25 μM 
dexamethasone, 0.5 mM IBMX and 1.0 μg/ml insulin.  
At day 6° of the differentiation process medium was changed to adipocytes maturation 
medium containing 89% DMEM, 10% FBS, 1% P/S and 1.0 μg/ml insulin. After day 12° the 
cells were kept in maintenance condition using basal medium without hormones. For the 
whole process, medium has been refreshed every two days. 
Adipocyte differentiation was tested using a specific dye for lipids, Oil Red O, observable 
under microscope. 
 
 
Figure 7: Experimental set-up for adipocytes differentiation with induction factors. 
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2.2 Blue Light treatment 
2.2.1 LED Characteristics  
As light source a BioLight LED lamp (Figure 8) provided by Philips Research 
(Eindhoven/Netherlands) was used (Lumileds LUXEON Rebel LXML-PR01-0275). 
According to the company’s specification, the LED device was distance and power adjusted 
to deliver a fixed irradiance of 23 mW/cm
2 
at the surface of irradiated cell culture plates 
(50mm distance from lamp casing). However, since the black plate, the lid and medium led to 
a power loss of about 50% due to light absorption, the irradiance was attenuated to about 12 
mW/cm
2. 
The peak wavelength, measured in this condition was given at λ= 453 nm (Figure 
9). Doses resulting from different irradiation times are shown in Table 1. 
 
   
Figure 8: BioLight LED lamp equipped with one power supply delivering 1 A at 300 V (direct current) to 
drive the LEDs via defined presets. The fan on the top protects the lamp against overheating, especially 
when using higher irradiances or longer irradiation times 
 
 
 
Figure 9: Emission spectrum of the Light-Emitting Diode from Koninklijke Philips N.V. 
(Eindhoven/Netherlands) with a peak wavelength of 453 nm.
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2.2.2 Light stimulation 
To assess the effects of light irradiation on cell proliferation, metabolism and gene expression, 
3T3L-1 cells were seeded in black 96-well plates with sterile clear flat bottom (Costar®).  
These plates prevent the light cross-talk between the wells and allow a direct microscopic cell 
viewing. After seeding, cells were incubated till confluence (48 h) at 37°C and 5% CO2. The 
medium was renewed every two days as reported by the differentiation protocol described in 
the section 2.1.1. According to the two different irradiation set-ups, 3T3-L1 were irradiated 
with a fixed irradiance of 23 mW/cm
2
 and constant light for 30 min or 60min respectively 
equal to a dose of 21.6 J/cm
2
 and 43.2 J/cm
2
 (Table 1) 
 
Time (min) Irradiance (mW/cm
2
) Energy density (J/ cm
2
) 
30 12 21.6 
60 12 43.2 
Table 1: Energy densities depending on the duration of light stimulation. Energy density [J/cm
2
] = 
Irradiance [mW/cm
2
] x Irradiation time [sec]. 
 
2.2.3 Experimental setup 
The effects of blue light treatments have been evaluated in two different phases of the 
process: during (Day0-14) and after cell differentiation (Day 15-21) (Figure 10). In both set-
ups black 96-well plates were used and a number of 1200 cells/well has been seeded. 
 
Days:  0    1    2    3    4    5    6    7    8    9    10    11    12    13    14    15    16    17    18    19    20    21        
Irradiation during differentiation process Irradiation on mature adipocytes
 
 
Figure 10: Time course of adipogenesis. 
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1° setup: Blue light treatment during differentiation process. 
3T3-L1 cells have been irradiated 30 minutes once a day for 14 consecutive days. This period 
covered all the differentiation process. Each black 96-well plate has been divided in three 
parts: 1/3 was irradiated daily from Day0 till Day14 (Col.# 1-4); 1/3 was irradiated only the 
first day of differentiation (Day0) and dark taped for the following days(Col.#5-8);1/3 was 
dark taped representing the untreated control (Col.#9-12). 
2°setup: Blue light irradiation after differentiation process. 
Mature adipocytes have been irradiated 30 or 60 minutes once a day for 7 consecutive days. 
Each black 96-well plates has been divided in three parts: 1/3 was irradiated daily for 60 
minutes (Col.#1-4); 1/3 was irradiated daily for 30 minutes (Col.#5-8);1/3 was dark taped 
representing the untreated control (Col.#9-12).  
 
Figure 11 shows plate lids used during irradiation. 
 
Apart from blue light irradiation, for both set-ups, treated and untreated samples were always 
kept under the same growing and environmental conditions.  
 
Figure 11: Lids of a black 96-well plate A) used for 30min daily irradiation during the 1°setup and 60min 
irradiation during 2°set-up. B) lid used for 30min irradiation Day0 during the 1°set-up and 30min irradiation 
during the 2° set-up. 
 
2.3 Staining and quantification 
Several stainings and associated quantifications were performed in order to confirm 
differentiation, quantify lipids and to make a relative estimate of cells number. 
Material and Methods 
18 
 
2.3.1 Oil Red O staining and quantification 
Independently from the different set-ups used during light stimulation, after 3h from the last 
irradiation the cells were washed twice with phosphate-buffered saline (PBS) and fixed in 4% 
paraformaldehyde for 30 minutes. After fixation, cells were washed three times and stained 
with Oil Red O (ORO) (Sigma Aldrich) solution (stock solution 0.5g ORO powder dissolved 
in 100% 2-propanol) for 1 hour at room temperature. Cells were washed again three times 
with water to remove unbound dye and were examined under a light microscope. The red oil 
droplets stained in the cells indicating lipid accumulation. 
To quantify the lipid accumulation, red oil droplets stained in the cells were extracted in 
100% 2-propanol. The absorbance was evaluated at 510nm using Infinite® 200 PRO 
microplate reader (TECAN). 
 
2.3.2 Hoechst and AdipoRed staining and quantification 
In order to evaluate differences in cell number between irradiated and no irradiated samples, a 
combined staining of Hoechst and Nile Red (AdipoRed) was performed. After treatment, cells 
were washed in PBS and fixed with PFA 4% for 30 minutes. After the incubation time, cell 
were washed again and stained with Hoechst 33342 (Sigma) for other 30 minutes. 
Measurements with Infinite® 200 PRO microplate reader (TECAN) were done setting the 
instrument with Ex/Em wavelengths 354/442 nm. Later on, AdipoRed assay (Lonza) was 
performed on the same samples, following the manufacturer’s protocol. AdipoRed is a 
solution of the hydrophilic stain Nile Red that enables the quantification of intracellular lipid 
droplets. When partitioned in a hydrophobic environment, Nile Red becomes fluorescent. The 
emission maximum of the fluorescent signal is dependent on the nature of the hydrophobic 
environment. Nile Red Fluorescence, when bound to protein or the phospholipids of the 
plasmalemma of a cell, is distinct from that produced when the stain is partitioned in droplets 
of triglyceride. Measurements were done setting the microplate reader with Ex/Em 
wavelengths 485/572 nm. 
 
2.4 Cell metabolism and proliferation assays 
Blue light effects were studied on metabolism and proliferation using various methods.  
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2.4.1 XTT assay  
Metabolic activity determined using Colorimetric Cell Viability Kit III from PromoKine 
(PromoCell). The assay is based on the reduction of the tetrazolium salt XTT (2, 3-bis-(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) into a colored formazan 
compound by mitochondrial enzymes. Since these enzymes are inactivated shortly after cell 
death, this is a reliable method for the detection of viable cells. In the presence of the activation 
reagent, N-methyl dibenzopyrazine methyl sulfate (PMS), mitochondrial enzymes of metabolic 
active and viable cells reduce the yellow tetrazolium salt XTT to a water-soluble, orange-coloured 
formazan dye. Therefore, the resulting absorbance intensities directly correlate with the activity of 
mitochondrial enzymes of viable and active cells metabolizing XTT. Following irradiation, a 
reaction mixture of XTT and PMS (1:200) was added to the medium (50% by volume) and 
incubated for 45 minutes at 37°C and 5% CO2. The absorbance of the formazan product can be 
measured directly from a 96-well plate without additional processing. For quantification 
spectrophotometric absorption measurements at 450 nm with a reference reading at 690 nm 
were carried out with Infinite® 200 PRO microplate reader (TECAN). Non-specific signals 
were identified by adding XTT/PMS only to cell culture medium. 
 
2.4.2 ATP assay 
Metabolic activity by ATP quantification was tested using the CellTiter-Glo® Luminescent 
Cell Viability Assay (Promega). This test is based on a luciferase reaction to measure the 
amount of ATP in cells. Light and oxyluciferin are formed upon the mono-oxygenation of 
luciferin, which is catalyzed by Ultra-Glo™ Recombinant Luciferase in the presence of Mg2+ ATP 
and molecular oxygen. Per well, 100 μl reagent were mixed with the same volume of culture 
medium. Lysing of the cells took place by 10 min incubation at RT and moderate shaking. In 
order to avoid luminescence loss opaque-walled 96-plates were used for measurements with 
Infinite® 200 PRO microplate reader (TECAN). Background signals were identified by 
including wells containing only medium. Read-outs correlate directly proportional to the ATP 
amount because cells lose the ability to synthesize this ribonucleotide triphosphate directly 
after loss of membrane integrity or a cytotoxic event. 
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2.4.3 BrdU ELISA 
Furthermore, Colorimetric BrdU Cell Proliferation ELISA from Roche Diagnostics GmbH 
(Mannheim/Germany) to quantitate cell proliferation based on the measurement of BrdU 
incorporation during DNA synthesis in proliferating cells, was used. BrdU labeling was 
performed directly after the blue light irradiation adding 10 μM BrdU for 24 hours at 37°C 
and 5% CO2. After 24 hours incubation time, the labeling medium was aspirated and cells 
were fixed for 30 minutes, while the DNA was denatured. This enabled an increased 
accessibility for the anti-BrdU antibody, which was incubated for 90 minutes, while free, 
unbound antibodies were removed by three subsequent washing steps with 1x PBS. As the 
antibody was conjugated to peroxidase, tetramethyl-benzidine was added for 3 minutes. Then, 
the reaction was stopped with 1M H2SO4. Infinite® 200 PRO microplate reader (TECAN) 
was used to quantify immune complexes at 450 nm with a reference reading at 690 nm. The 
test was performed only during the differentiation process (1° set-up) on day: 0-2-6-10-14. 
For each time point two replicates for two repetitions were done. 
 
2.5 Mitochondrial function – ROS generation 
Generation of mitochondrial ROS mainly takes place at the electron transport chain located on the 
inner mitochondrial membrane during the process of oxidative phosphorylation (OXPHOS). 
Since mitochondria are potential targets and initiators of the blue light's photosensitization processes, 
the amount of intracellular ROS was quantified following irradiation. 
 
2.5.1 Quantification of intracellular ROS 
2’,7’ –dichlorofluorescin diacetate (DCFDA) (MERCK) was used to measure intracellular 
ROS. DCFDA is a fluorogenic dye that measures hydroxyl, peroxyl and other reactive oxygen 
species (ROS) activity within the cell. After diffusion into the cell, DCFDA is deacetylated by 
cellular esterases to a non-fluorescent compound, which is later oxidized by ROS into 2’,7’–
dichlorofluorescein (DCF). DCF is a highly fluorescent compound which can be detected by 
fluorescence spectroscopy with excitation / emission at 485 nm / 535 nm. After the 
irradiation, cells were washed in PBS. DCFDA was added at the concentration of 20µM for 
45 minutes in medium serum-free to avoid false results from esterases contained in it. At the 
end of incubation time, cells were washed in PBS and fluorescent signal measured with 
Infinite® 200 PRO microplate reader (TECAN). 
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2.6 RNA-Isolation 
RNA was extracted using the RNeasy Lipid Tissue Mini Kit (Qiagen). The lysis step was 
adapted to cell culture by adding 55.5µl of Qiazol into each well. The other steps were 
performed following manufacturer’s protocol. RNA concentration and quality were measured 
using a Spark™ 10M multimode microplate reader. In addition RNA purity was determined by 
measuring the absorbance ratio at A260/280 with acceptable values of 1.7 – 2.1. RNA integrity 
was assessed by capillary electrophoresis on Agilent 2100 Bioanalyzer (Agilent 
Technologies, CA, USA) and RNA integrity number (RIN) was calculated by a specific 
Agilent software tool. Only samples with RIN values higher than or equal to 7.0 were used for 
gene expression analysis. 
 
2.7 Gene expression 
Gene expression analysis is a widely used tool in biology and medicine that can provide 
information about the expression of genes in different tissues or under certain conditions. In 
this study, the effect of blue light irradiation on gene expression was investigated using RNA 
sequencing techniques. 
 
2.7.1 RNA sequencing 
RNA sequencing was done by BGI Tech Solutions Co. (Hong Kong). For RNA sequencing, 
three RNA samples per condition (irradiated and no-irradiated) were analyzed by using the 
BGISEQ-500 method. 
 
2.7.2 Bioinformatic evaluation 
To analyse the RNA sequencing data the RBioconducor software was used. Data Alignment 
was done by Rsubread software. For annotation the entrez-based software package 
TxDb.Hsapiens.UCSC.hg19.knownGene was used and differential Gene Expression Analysis 
was performed by a DESeq2 package. As a level of the significance α= 0.05 with FDR 
correction was chosen. The normalized enrichment score (NES) is the primary statistic for 
examining gene set enrichment results. By normalizing the enrichment score, GSEA accounts 
for differences in gene set size and in correlations between gene sets and the expression 
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dataset; therefore, the normalized enrichment scores (NES) can be used to compare analysis 
results across gene sets. GSEA was performed to determine statistically differences between 
blue light irradiation and no-light controls. Pathway analysis was done with the help of the 
public external KEGG database to transform the list of individual genes into a set of 
pathways.
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3 Results 
3.1 Adipogenic differentiation 
The first differentiation tests were conducted in 25cm
2
 flasks. The 3T3-L1 were seeded at a 
density of 2000-3000 cells/ cm
2 
and treated for adipogenic differentiation for 14 days. During 
this period the cells were observed and, at predetermined times, stained with Oil Red O and 
photographed under an optical microscope. (Figure 12 A-C)  
The control is represented by cells maintained in complete DMEM without inductor factors. 
In 3T3-L1 cultures induced to adipogenic differentiation it is possible to observe that, after 6 
days (Day 5) of treatment with the medium supplemented with inductor factors, the cells 
begin to lose the typical fibroblastic conformation that characterizes the control cultures and 
the appearance of small intracellular droplets, mostly located in a peripheral position along 
the cytoplasmic membrane. On Day 9, under stimulation, the cells continue to accumulate 
lipids in the form of intracellular drops. (Figure 13) 
From day 10, the adipogenic induction medium is replaced with the maintenance medium that 
allows adipogenic differentiation to be maintained and completed. After 14 days of treatment 
most of the cells are positive for Oil Red O staining, the 3T3-L1 cytoplasm is entirely 
occupied by large intracellular staining positive deposits and the nucleus undergoes a 
peripheral shift. The increase in the number of intracellular drops causes most cells to show a 
cytoplasm rich in lipid deposits. The 3T3-L1 cell cultures used as control do not show the 
appearance of the drops at any of the times examined and in fact they are negative for Oil Red 
O staining; they maintain the fibroblast-like shape and the nucleus is clearly evident in the 
centre of the cells. These differences are marked by a combined staining of Haematoxylin/ 
Eosin and Oil Red O (Figure 12 D-E). Subsequently, in order to choose the experimental 
number of starting cells, various tests were conducted in which the cells were plated at 
different densities and treated according to the adipogenic differentiation protocol. Based on 
the results obtained, it was established that the initial density of 1200 cells/cm
2
 is the one that 
best supports the adipogenic differentiation of 3T3-L1 according to the type of plate used as 
black 96-well plate. 
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Figure 12 :Oil Red O staining shows changes during different stages of adipogenesis A) no-induced 3T3-L1 negative to Oil Red O staining, induced 3T3-L1 positive to 
Oil Red O B) at day 5 and C) at day 14. Nuclei and cytoplasm are stained with Hematoxylin and Eosin in D) no-induced 3T3-L1 and E) induced and completely 
differentiated adipocytes.
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Figure 13: Morphological changes during adipogenesis. The control is represented by no stimulated 3T3-L1 cells. 3T3-L1 cells treated with inductor factors show 
accumulation of lipid droplets and morphology changes from spindle shape to rounded shape. 
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3.2 Oil Red O quantification 
Since intracytoplasmic lipid accumulation seems to be directly proportional to the extent of 
differentiation, Oil Red O staining was performed at the last day of the experiment after cell 
fixation and examined under a light microscope. Three different microscopic fields (5x, 10x 
and 20x magnifications) per culture were photographed (Figure 14). A first microscopic 
analysis showed that a normal and complete differentiation took place in non-irradiated 
cultures (controls) where almost all the cells appeared as mature adipocytes. A decrease in the 
percentage of positive cells to the staining came up in irradiated cultures depending on the 
number of treatments. Cells irradiated at Day0 appeared partially differentiated compared to 
daily irradiated cells that looked still like fibroblasts.  
Recently, Oil Red O staining is also being used for quantitative analysis of adipocyte 
differentiation. To enable quantitative measurements, the dye is commonly eluted from the 
cells using 2-propanol, and absorbance is photometrically determined at 510 nm. Figure 15 
shows the negative trend related to the lipid amount after dye extraction. After a single or 
multiple treatments a decrease of 17% (p<0.0001) and 38% (p<0.0001) was respectively 
found at Day0 and after 14 days. These results suggest that blue light can modulate the 
differentiation process probably causing a stop of it; this is also reflected in reduced lipid 
accumulation in treated cultures. 
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Figure 14: Oil Red O staining. Different microscopic fields show the effect of blue light treatment during differentiation process. Single or multiple 
irradiation lead to reduced cellular differentiation. Cells irradiated for 14 days still appear in their fibroblastic shape.
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***
***
 
Figure 15: Oil Red O quantification of differentiating 3T3-L1 cells. Comparison of quantitative staining of 
wells treated with blue light on Day0 or for 14 days. Data are shown as box plots with the median, upper and 
lower quartile (interquartile range (IQR)) and whiskers (1.5 x IQR). Each box plot represents 3 repetitions x 3 
replicates. Statistical significance was determined with the parametric Student t-test. Values significantly 
different from control are indicated as ***p<0.0001 
 
The staining was performed also on mature adipocytes irradiated for 30 or 60 minutes for 7 
days. Oil Red O was eluted and quantify in the same way above. The microscope analysis did 
not reveal  significant differences  between controls and treated samples (Figure 16). Only a 
slight increase around 5% in lipid amount was shown in cultures irradiated for 30 minutes 
(p=0.0419) or 60 minutes (p=0.0637) after Oil Red O quantification. Light irradiation has not 
shown effects on lipid loss in mature adipocytes even suggesting a slight, though not 
significant, increase of them. (Figure 17) 
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Figure 16: Oil Red O staining. No effect of blue light treatment after differentiation process. 
 
 
 
Figure 17: Oil Red O quantification of mature adipocytes. Comparison of quantitative staining of wells 
treated with blue light for 30 or 60 minutes after complete differentiation. Data are shown as box plots with 
the median, upper and lower quartile (interquartile range (IQR)) and whiskers (1.5 x IQR). Each box plot 
represents 3 repetitions x 3 replicates. Statistical significance was determined with the parametric Student t-test. 
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3.3 Assessment of blue light effects on cell metabolism assays 
Changes in the metabolism following blue light irradiation were assessed during and after 
adipogenic differentiation of 3T3-L1 cells. Metabolism was studied based on the activity of 
mitochondrial enzymes and ATP concentration in cell cultures. 
 
3.3.1 XTT results are affected by blue light irradiation during but no after 
differentiation phase  
XTT assays were performed to analyse changes in cell metabolism induced by blue light 
irradiations. Viable cells metabolize the XTT reagent and the product is measured 
spectrophotometrically. To assess the duration of the effects over time, XTT tests were 
performed after two different time points: directly after the last irradiation (45 min, XTT 
incubation time) or 24 hours later. 
To see the inhibitory effects of blue light, for this study the irradiation time of 30 minutes 
(21.6 J/cm
2
) was tested during the differentiation process irradiating the cells only the first 
day (Day0) or for 14 days under adipogenic stimuli. 
As shown in the figure 18 , already 45 min after the last irradiation a metabolism decrease 
was observed by 9% (p<0.001) with a single irradiation on Day0 and slightly pronounced 
effect till 10% (p<0.001) for multiple irradiations. No recovery in metabolism occurred after 
24 hours as evidenced by an almost perfect matching of the results.  
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Figure 18: Changes in metabolic activity of 3T3-L1 cells. Blue light treatments were performed with 21.6 
J/cm
2
 at Day0 or for 14 days. XTT tests were carried out 45min or 24h following the last irradiation. Fold 
changes were evaluated versus time matched, no-irradiated controls. Data are represented as mean ± SD (N = 3 
repetitions, 3 replicates). Statistical significance was determined with the parametric Student t-test. Values 
significantly different from control are indicated as **p<0.001. 
 
After complete differentiation, 3T3-L1/adipocytes were irradiated from Day15 for the 
following 7 days, for 30 (21.6 J/cm
2
) or 60 (43.2 J/cm
2
) minutes. To evaluate the effects of 
blue light in the short or long time, XTT tests were performed at Day21 directly after last 
irradiation or 24h later on. 
As shown in figure 19, directly after the last irradiation (45min, XTT incubation time) cells 
irradiated for 30 or 60 minutes have a different behaviour. While the shortest irradiation leads 
to a decrease in the metabolism of around 6% (p<0.0001), the longer irradiation showed an 
increase in cell metabolism of 4% (p=0.0007) compared to the control with a difference of 
10% (p<0.0001) compared to 30 minutes irradiation.  
After 24h the situation seems to be recovered for the longer irradiation; the treated cells differ 
from the control by an insignificant decrease of 1.8% (p = 0.095). Instead 30 minutes 
irradiation showed the same trend after 24h, a decrease of 5.3% (p<0.0001), suggesting that 
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this irradiation time, compared to the longer irradiations, can lead to stronger and irreversible 
metabolic effects, at least for 24h.  
 
***
**
 
Figure 19: Changes in metabolic activity in mature adipocytes. Blue light treatments were performed for 7 
days after differentiation for 30 or 60 minutes equivalent to doses of 21.6 J/cm
2
 and 43.2 J/cm
2
. XTT tests were 
carried out 45min or 24h following the last irradiation. Fold changes were evaluated versus time matched, no-
irradiated controls. Data are represented as mean ± SD (N = 3 repetitions, 3 replicates). Statistical significance 
was determined with the parametric Student t-test. Values significantly different from control are indicated as 
**p<0.001, ***p<0.0001. 
 
 
3.3.1.1 Single or multiple blue light exposures at 21.6 J /cm2 during differentiation lead 
to lead to a
 
decreased in the ATP concentration while an opposite trend is 
reported in mature adipocytes 
A second metabolic test related to viability and cell number was performed to confirm the 
results obtained using the XTT tests. Since ATP plays an important role in energy exchange 
in biological systems such a measurement is fundamental to study living processes and 
mitochondria activity. A bioluminescent method for ATP quantification was chosen. 
As shown in figure 20, 30min of irradiation of maturing 3T3-L1 cells led to a decrease in 
ATP concentration directly after the last irradiation (10min, ATP incubation time) in both 
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treatment conditions. A drop around 7% (p <0.001) was recorded in samples irradiated at the 
first day of induction (Day0) and a more prominent effect was reached, around 20% (p 
<0.001), for multiple and consecutive irradiations. Even though changes in ATP levels 
represent a fast response, the effect mediated by blue light last over time following the same 
trend after 24h, though signs of recovery were observed. After 24h ATP levels were reduced 
by 3% (p 0.094) and by 13% (p <0.001) after single or multiple irradiations. 
 
**
**
**
 
Figure 20: Changes in ATP concentration in 3T3-L1/preadipocytes during the differentiation process. 
Blue light treatments were performed with 21.6 J/cm
2 
at Day0 or for 14 days. ATP levels were quantified 10min 
or 24h following the last irradiation. Fold changes were evaluated versus time matched, non-irradiated controls. 
Data are represented as mean ± SD (N = 3 repetitions, 3 replicates). Statistical significance was determined with 
the parametric Student t-test. Values significantly different from control are indicated as **p<0.001 
 
 
Multiple exposures at different blue light doses on mature adipocytes showed an increase in 
their ATP levels (Figure 21). Following 30 or 60 minute of irradiation for 7 consecutive days, 
cells have risen the ATP amount in a dose dependent way with a growth of 15% and 20% 
(p<0.0001) respectively after 30 and 60 minutes of treatment when the quantification was 
performed directly after the last irradiation. 
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After 24h, cells irradiated for 30 minutes restored basal ATP levels; the same cannot be 
argued for longer irradiations. Although ATP amount decreased over time after 24h, the 
levels stayed higher than control with an increase equal to 13% (p<0.0001) in cells daily 
irradiated for 60 minutes. 
 
***
***
***
 
Figure 21: Changes in ATP concentration in 3T3-L1/differentiated cells (mature adipocytes). Blue light 
treatments were performed for 7 days after differentiation for 30 or 60 minutes equivalent to doses of 21.6 J/cm
2
 
and 43.2 J/cm
2
. ATP levels were quantified 10min or 24h following the last irradiation. Fold changes were 
evaluated versus time matched, non-irradiated controls. Data are represented as mean ± SD (N = 3 repetitions, 3 
replicates). Statistical significance was determined with the parametric Student t-test. Values significantly 
different from control are indicated as ***p<0.0001 
 
 
3.4 Assessment of blue light effects on cell proliferation 
3.4.1 Chronic blue light exposure reduced cell proliferation rate during adipogenesis 
Considering the difficulty in trypsinizing and detaching cells when differentiation process is 
triggered, no cell count in an ordinary way was possible. To overcome this problem, a 
quantitative estimation of the cells number was made by staining the nuclei with Hoechst dye. 
After treatment with blue light, cells were fixed, stained and the fluorescence was read out 
spectrophotometrically. Significant results were obtained for cells treated during 
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adipogenesis. Treatment of 30 minutes of blue light at Day0 showed a fluorescence reduction 
of 13% (p< 0.0001) and of 31% (p< 0.0001) for daily treatments compared to control. This 
can be correlated to a reduced cells number.  
A second lipid-specific staining was used to confirm the results obtained from the Oil Red O 
extraction. AdipoRed assay was conducted on the same cells previously stained with Hoechst. 
A reduction in cellular lipids, as previously highlighted by Oil Red O staining, was noted. 
Compared results between cell number and lipid amount are shown in the figure 22. 
 
*** *** ***
 
Figure 22: Comparison between nuclei quantification (Hoechst) and lipid accumulation (AdipoRed) 
during adipogenesis. Data are shown as box plots with the median, upper and lower quartile (interquartile range 
(IQR)) and whiskers (1.5 x IQR). Each box plot represents n=3 repetitions x 3 replicates. Statistical significance 
was determined with the parametric Student t-test. Values significantly different from control are indicated as 
***p<0.0001 
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In contrast, treatments on mature adipocytes showed no significant changes in cell count or 
lipid amount (Figure 23). 
  
 
Figure 23: Comparison between nuclei quantification (Hoechst) and lipid accumulation (AdipoRed) in 
irradiated adipocytes. Data are shown as box plots with the median, upper and lower quartile (interquartile 
range (IQR)) and whiskers (1.5 x IQR). Each box plot represents n=3 repetitions x 3 replicates. Statistical 
significance was determined with the parametric Student t-test. 
 
3.4.2 BrdU tests showed a linear decrease of DNA synthesis after consecutive 
irradiations 
In order to confirm the anti-proliferative effects of the dose of 21.6 J/cm
2
, a colorimetric Elisa 
test based on BrdU incorporation was performed at different harvesting times after 30min of 
blue light irradiation. As the doubling time of 3T3-L1 cells is 21h, an effect on BrdU 
incorporation was not expected in shorter times. After the irradiation BrdU was added on 
Day0, Day2, Day6, Day10 and Day14 to follow the trend of the proliferation rate and 
outcomes were read out after 24h.  
Compared to the untreated control, DNA synthesis diminished in a dose dependent way over 
the time. Decrease was less pronounced following one irradiation on Day0 with a slight 
decrease of 4% (p<0.0001). This effect enhanced to 16% (p<0.0001) with three consecutive 
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irradiations accounting for 64.8 J/cm
2
 total dosage (3x(24h)), whereas 7 irradiations, yielding 
a dosage of 151.2 j/cm
2
 (7x(24h)), led to a reduction of 33% (p<0.0001). Maximum reduction 
of 48% (p<0.0001) is obtained after 11 consecutive irradiations, dosage of 237.6 J/cm
2
, after 
which a plateau is reached as shown on Day14 (324 J/cm
2
) (Figure 24). 
 
***
***
***
*** ***
 
Figure 24: Changes in DNA synthesis in 3T3-L1 cells during the differentiation process. Consecutive 
irradiation with 21.6 J/cm
2
 of blue light were performed every 24 hours. BrdU ELISAs were carried out at 24 
hours after last irradiation. Fold changes were evaluated versus time- matched, non-irradiated controls. Data are 
represented as mean ± SD (N = 2 repetitions, 2 replicates). Values significantly different from control are 
indicated as ***p<0.0001 
 
 
3.5 Evaluation of ROS levels 
Since reactive oxygen species (ROS) can influence signaling and cell functions, DCFH-DA 
fluorescent probe was used to measure intracellular generation of H2O2 and other oxidizers 
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and to monitor changes in redox signalling in response to oxidative stimuli, such as blue light. 
DCFH-DA was added in serum free medium to the cells after the last treatment. 
As evident in figure 25, ROS production increased in cells treated 30min at Day0 but 
decreased for daily irradiation. The high standard deviation is probably due to the instability 
of the probe or the capability of the intermediate radical, DCF
-
, formed from the one-electron 
oxidation of DCFH, to rapidly react with O2 to produce anion superoxide. The dismutation 
yields additional H2O2, which can establish a redox-cycling mechanism leading to artificial 
amplification of the fluorescence signal intensity. 
 
 
Figure 25 Changes in ROS levels of 3T3-L1 cells measured directly after the last irradiation to 21.6 J/cm
2 
. 
DCFH-DA probe was excited at λEx = 485 nm, while its fluorescence emission was measured at λEm =535 nm. 
Fold changes were evaluated versus time- matched, non-irradiated controls. Data are represented as mean ± SD 
(N = 2 repetitions, 2 replicates). 
 
More stable results were obtained on mature adipocytes. The irradiation with 30 or 60 
minutes did not lead to an increase of ROS production as instead was expected (Figure 26).
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Figure 26: Changes in ROS levels of differentiated adipocytes measured directly after the last irradiation 
to 21.6 J/cm
2 
and 43.2 J/cm
2 
. DCFH-DA probe was excited at λEx = 485 nm, while its fluorescence emission 
was measured at λEm =535 nm. Fold changes were evaluated versus time- matched, no-irradiated controls. Data 
are represented as mean ± SD (N = 2 repetitions, 2 replicates). 
 
3.6 Gene expression 
3.6.1 Gene expression analysis 
Following irradiation, time-dependent changes in the gene expression were studied for both 
set ups. Cells were harvested and RNA extracted after the last irradiation, respectively at day 
14 for the first set up and day 21 (7
th
 experimental day) for the second set-up, with three 
replicates for each condition tested, light-treated and untreated control. 
Following distribution analysis and batch normalization for separate experiments, the 
similarity in gene expression pattern was visualized by the tendency of points to fall near the 
diagonal, as measured by the Pearson’s correlation coefficient. Correlation heatmaps showed 
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distribution of the samples in three clusters for the first set up, moreover the dendrogram 
presented a similar relation between control and irradiated samples at Day0. 
In contrast, in the second set up the clustering was not so evident showing an ambiguous 
relation between the different samples probably due to some problems during the irradiation 
or RNA extraction (Figure 27). 
From this point on, for better exposure and understanding, data from gene expression analysis 
will be treated separately for the two set-ups. 
 
  
Figure 27: Representative Pearson’s correlation heatmap showing cluster analysis of untreated (control, 
N= 1 repetition, 3 replicates) and treated samples (N= 1 repetition, 3 replicates) following single or 
multiple irradiation according to the setting used in each set-up. 
 
 
3.6.1.1 Gene expression analysis 1° set-up: blue light irradiation on maturing 
preadipocytes (3T3-L1 cells) 
RNA seq screneed 24421 genes in total, 5591 significantly expressed (FDR <0.05) only in 
treated samples. Since the previous tests showed dose-dependent effects, it was investigated 
whether, in addition to the metabolic response, also gene expression followed the same trend. 
However, in relation to the number of blue light irradiations, differentially adjusted genes 
were increased in total number from 2882 de-regulated genes after one day of treatment 
(Day0), to 5124 genes after 14 days of treatment with 2415 genes triggered commonly 
(Figure 28). According to the results seen above, this data suggests that probably already a 
single irradiation on the first day of differentiation can influence the expression of important 
genes involved in cell differentiation and proliferation. 
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Figure 28: Venn diagram showing the number of significantly (FDR<0,05) commonly or differentially 
expressed genes in differentiating 3T3-L1 cells following single (Day0) or multiple (14 days) blue light 
irradiations.  
 
In the table 2 the number of up- and down-regulated genes is listed for both treatments. 
Samples irradiated at Day0 have shown a majority number of down-regulated genes, which 
were even more in samples treated daily. Unlike a single dose of irradiation, 14 irradiations 
have shown a number of up- or down-regulated genes which did not differ much from each 
other. The data therefore have shown that treatment with blue light has tended to lower gene 
expression levels during adipocyte differentiation. However, differential changes emerged 
after irradiation were present already in the early phase of the differentiation process 
suggesting the high sensitivity of the cells in this phase with effects that last over the time. 
 
 
Table 2: Number of significantly up and down-regulated genes differentially expressed in differentiating 
3T3-L1 cells following single (Day0) or multiple (14 days) blue light irradiations.  
 
Thereafter, Gene Set Enrichment Analysis (GSEA) was performed using Kyoto Encyclopedia 
of Genes and Genomes (KEGG) database to transform the list of individual genes into sets of 
pathways. Considering a ranked differentially expressed genes a Normalized Enrichment 
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Scores (NES) was used to indicate the distribution of the pathway within the list. Negative or 
positive NES indicates a shift of gene towards the bottom or the top of the list representing 
respectively down- or up-regulated pathways. Table 3 accounts the number of de-regulated 
KEGG pathways for both treatment conditions. Starting from a total gene set number equal to 
281 for both irradiation times tested, the number of down-regulated pathways for treated 
samples at Day0 was higher than the up-regulated pathways. Of these de-regulated pathways 
less than half were significant with a p-value < 0.05 and, although it did not differ much, the 
number was even more reduced if it was considered an adjusted p-value (FRD) with the same 
cut-off; these pathways were therefore highly significant. A contrary trend occurred as a result 
of daily irradiation where up-regulated pathways prevailed over down-regulated pathways. 
Also in this case the number of significantly regulated pathways (p-value < 0.05) was reduced 
without departing in large numbers from the highly significant ones (FDR < 0.05). 
 
 
Table 3: Number of differentially expressed KEGG pathways in differentiating 3T3-L1 cells following 
single (Day0) or multiple (14 days) blue light irradiations. Starting from an overall gene set number of 281, 
total numbers of up- or down-regulated pathways are shown. In addition the number of significantly enriched 
pathways is listed for different significance levels at nominal p- value < 0,05 or < 0,01 and at adjusted p-value 
(FDR) <0,05. 
 
Only de-regulated pathways with an adjusted p-value (FDR) ≤ 0.05 have been taken into 
account for the subsequent analysis. The pathways were sorted into 6 main categories by 
KEGG for a simpler observation. This division helps to understand the effects and 
interactions after blue light treatment (Figure 29). For both irradiation times most down-
regulated pathways belong to the Metabolism category. This result confirmed those obtained 
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from previous metabolic tests, in which following blue light treatment a reduced metabolic 
activity was found. Many metabolic pathways were involved in the production or 
consumption of ATP mostly related to the oxidative phosphorylation process. Oxidative 
phosphorylation gene set was down-regulated after blue light treatment suggesting 
mitochondrial damage or dysfunction already at low dose. Related to the main category of 
Metabolism also the subcategory of Lipid metabolism was found down-regulated reflecting a 
reduction in lipid production and adipocyte differentiation (Table 4). 
 
 
Figure 29: (A) Distribution of significantly enriched pathways (FDR < 0,05) sorted by main categories of 
KEGG. Groups are formed by the respective doses/irradiation times. The numbers around the pie charts 
indicate the number of deregulated pathways contained in each category. (B) Comparison of significant 
pathway list with NES < 0 and (C) NES > 0 at different irradiation time. 
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1. Metabolism
      30min x Day0         30min x 14Days
NES
Adjusted 
p-value
NES
Adjusted 
p-value
1.0. Global and overview maps
Metabolic  pathways -2.51 0.001302 -2.55 0.00375
Carbon  metabolism -2.81 0.001302 -2.93 0.002066
2-Oxocarboxylic  acid  metabolism -2.12 0.001302 -2.11 0.002951
Fatty  acid  metabolism -2.41 0.001302 -2.74 0.002066
Biosynthesis  of  amino  acids -2.42 0.001302 -2.13 0.002066
1.1. Carbohydrate metabolism
Glycolysis    Gluconeogenesis -2.36 0.001302 -2.08 0.002066
Citrate  cycle  (TCA  cycle) -2.51 0.001302 -2.75 0.002066
Pentose  phosphate  pathway -2.13 0.001302 -1.96 0.005409
Fructose  and  mannose  metabolism -2.09 0.001302 -1.61 0.057377
Starch  and  sucrose  metabolism -1.89 0.00341 -1.73 0.040714
Pyruvate  metabolism -2.44 0.001302 -2.68 0.002066
Glyoxylate  and  dicarboxylate  metabolism -2.32 0.001302 -2.5 0.002066
Propanoate  metabolism -2.48 0.001302 -2.82 0.002066
1.2. Energy metabolism
Oxidative  phosphorylation -2.74 0.001302 -2.97 0.002066
1.3. Lipid metabolism
Fatty  acid  elongation -1.67 0.040983 -1.79 0.015703
Fatty  acid  degradation -2.22 0.001302 -2.4 0.002066
Steroid  biosynthesis -2.14 0.001302 -2.2 0.002066
Glycerolipid  metabolism -2.16 0.001302 -2.22 0.002066
Glycerophospholipid  metabolism -2.08 0.001302 -2.09 0.002066
Arachidonic  acid  metabolism -1.71 0.032653 -1.43 0.156942
Biosynthesis  of  unsaturated  fatty  acids -1.94 0.001302 -2.15 0.002066
1.4. Nucleotide metabolism
Pyrimidine  metabolism 0.95 0.752552 1.79 0.00286
1.5. Amino acid metabolism
Alanine,  aspartate  and  glutamate  metabolism -1.88 0.001302 -1.62 0.058565
Glycine,  serine  and  threonine  metabolism -1.76 0.017223 -1.3 0.245916
Cysteine  and  methionine  metabolism -1.8 0.013293 -1.46 0.11524
Valine,  leucine  and  isoleucine  degradation -2.61 0.001302 -2.96 0.002066
Lysine  degradation -1.83 0.005277 -1.57 0.050487
Tyrosine  metabolism -1.74 0.019665 -1.66 0.059321
Tryptophan  metabolism -1.91 0.001302 -1.8 0.024021
1.6. Metabolism of other amino acids
beta-Alanine  metabolism -2.01 0.001302 -1.96 0.006481
Glutathione  metabolism -1.76 0.013293 0.93 0.683004  
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1.8. Metabolism of cofactors and vitamins
Porphyrin  and  chlorophyll  metabolism -1.75 0.021895 -1.06 0.491311
Terpenoid  backbone  biosynthesis -2 0.001302 -2.24 0.002066
1.11. Xenobiotics biodegradation and metabolism
Metabolism  of  xenobiotics  by  cytochrome  P450 -1.86 0.007397 -1.5 0.098247
Drug  metabolism -1.7 0.030891 -1.31 0.230529  
Table 4: Significantly deregulated pathways belonging to KEGG’s main category ‘Metabolism’. The main 
category is divided into 13 subcategories in total (only pathways related to 9 subcategories are significant and 
shown in the table). Significantly deregulated pathways are shown in the table with their respective NES and 
adjusted p-values. Down-regulated (Up-regulated) pathways are indicated by the negative (positive) NES 
coloured in green (red). 
 
The table 5 shows most significant pathways of the second main category “Genetic 
information processing”. Except for protein export pathway, all the other considered 
pathways were up-regulated with effects increased according to the number of the treatments. 
The same trend in all subcategories was not surprising since mechanisms such as 
transcription, translation and downstream folding or protein degradation processes were all 
closely related. Is known that gene expression is regulated at both the transcriptional and post-
transcriptional levels in eukaryotic transcriptomes. Moreover, several mechanisms involved in 
transcriptional regulation can directly affect subsequent post-transcriptional gene regulation. 
Blue light treatment could affect both levels during 3T3-L1 differentiation process. In 
addition, many of the listed pathways as mRNA surveillance, ubiquitin mediated proteolysis, 
base excision repair, nucleotide excision repair, mismatch repair, are related to systems of 
DNA repair or degradation of damaged molecules. The up-regulation of these pathways 
suggested that blue light irradiation, especially if prolonged, can modulate damage at different 
biological levels. The up-regulation of DNA replication pathway is not directly related to the 
proliferation or the amount of cells DNA; it reflects the expression of proteins and enzymes 
required for DNA replication such as DNA polymerase, DNA helicase and others. 
Deregulation of this path was therefore not in contrast to the results obtained from the 
previous cell proliferation tests. 
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2. Genetic Information Processing
      30min x Day0       30min x 14Days
NES
Adjusted 
p-value
NES
Adjusted 
p-value
2.1. Transcription
Spliceosome 2.1 0.0042064 2.26 0.002066
2.2. Translation
Ribosome biogenesis in eukaryotes 0.72 0.9997707 1.96 0.002066
Ribosome 1.77 0.0042064 1.78 0.002066
RNA transport 1.08 0.4584289 2.07 0.002066
mRNA surveillance pathway 0.68 0.9997707 1.54 0.030225
2.3. Folding, sorting and degradation
Protein export -1.68 0.0409834 -1.7 0.035718
Ubiquitin mediated proteolysis 0.84 0.9616463 1.58 0.010012
2.4. Replication and repair
DNA replication 2.04 0.0022365 2.39 0.002066
Base excision repair 0.87 0.8373597 1.58 0.047274
Nucleotide excision repair 1.61 0.0310459 1.84 0.00286
Mismatch repair 1.35 0.2352356 1.87 0.004327  
Table 5: Significantly deregulated pathways belonging to KEGG’s main category ‘Genetic Information 
Processing’. The main category is divided into 4 subcategories. Significantly deregulated pathways are shown in 
the table with their respective NES and adjusted p-values. Up-regulated (Down-regulated) pathways are 
indicated by the positive (negative) NES coloured in red (green). 
 
The third main category “environmental information processing” includes several signal 
transduction pathways such as AMPK, TNF, NF-kappa B (NF-kB) which are known to be 
involved in the regulation of cell metabolism, proliferation, growth and apoptosis. Three of 
them TNF, NF-kB and cytokine, were strongly up-regulated in both single and multiple 
treatments suggesting an activation of signal cascade typical of inflammatory process. In 
addition, also AMP-activated protein kinase (AMPK) signalling was de-regulated in opposite 
direction. AMPK is an essential "fuel gauge," implicated in the regulation of energy balance 
and metabolism including glucose transport, gluconeogenesis, lipogenesis, and lipolysis and 
sterol synthesis. His involvement has been demonstrated in the development and function of 
adipose tissue.  
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3. Environmental Information Processing
       30min x Day0         30min x 14Days
NES
Adjusted 
p-value
NES
Adjusted 
p-value
3.1. Membrane transport
ABC transporters -1.71 0.031046 -1.69 0.035718
3.2. Signal transduction
NF-kappa B signaling pathway 1.35 0.140425 1.56 0.039508
HIF-1 signaling pathway -2.14 0.001302 -1.75 0.007735
AMPK signaling pathway -2.13 0.001302 -2.34 0.002066
Hippo signaling pathway 1.47 0.034044 1.1 0.405693
Hippo signaling pathway - multiple species 1.79 0.014704 1.24 0.304142
TNF signaling pathway 1.55 0.026383 1.65 0.010012
3.3. Signaling molecules and interaction
Cytokine-cytokine receptor interaction 1.21 0.235236 1.49 0.037398  
Table 6: Significantly deregulated pathways belonging to KEGG’s main category ‘Environmental 
Information Processing’. The main category is divided into 3 subcategories. Significantly deregulated 
pathways are shown in the table with their respective NES and adjusted p-values. Up-regulated (Down-
regulated) pathways are indicated by the positive (negative) NES coloured in red (green). 
 
Fourth main category includes “cellular processes”. Gene expression results shown up-
regulation in transport processes as lysosome and endocytosis systems. Peroxisome pathway, 
that contributes at many crucial metabolic processes such as fatty acid oxidation, biosynthesis 
of either lipids or free radical detoxification, is strongly down-regulated in both treatments. 
Concerning the subcategory “4.2. Cell growth and death” the cell cycle, p53 signalling and 
cellular senescence pathway are up-regulated for both conditions with higher significance for 
daily treatments (Table 7). 
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4. Cellular Processes
       30min x Day0         30min x 14Days
NES
Adjusted 
p-value
NES
Adjusted 
p-value
4.1. Transport and catabolism
Lysosome 1.53 0.026383 0.89 0.7704134
Endocytosis 1.22 0.125731 1.41 0.0253222
Peroxisome -2.51 0.001302 -2.87 0.0020656
4.2. Cell growth and death
Cell cycle 1.66 0.008966 2.08 0.0020656
Oocyte meiosis 1.3 0.133408 1.65 0.0100118
p53 signaling pathway 1.37 0.121768 1.63 0.0208405
Apoptosis 0.93 0.818856 1.47 0.0384984
Ferroptosis -1.72 0.020172 -1.27 0.2463162
Cellular senescence 1.02 0.629387 1.67 0.0031876
4.5. Cell motility
Regulation of actin cytoskeleton 1.41 0.024449 1.54 0.0099711  
Table 7: Significantly deregulated pathways belonging to KEGG’s main category ‘Cellular Processes’. 
The main category is divided into 5 subcategories (only pathways related to 3 subcategories are significant and 
shown in the table). Significantly deregulated pathways are shown in the table with their respective NES and 
adjusted p-values. Up-regulated (Down-regulated) pathways are indicated by the positive (negative) NES 
coloured in red (green). 
 
Fifth main KEGG category is “Organismal Systems” (Table 8). Most of the subcategories 
were down-regulated. Since all the pathways related to endocrine systems, except oocyte 
maturation, are connected to adipocytes, according to the hypothesis of adipocyte 
differentiation block induced by blue light, they were down-regulated as expected. It is 
important to keep in mind that the analysis was carried out by comparing the gene expression 
between the irradiated cells which were poorly differentiated after the treatment, and the 
controls which, by completing their differentiation process, result in mature adipocytes. 
Massive was de-regulation in the opposite direction for the pathways included in the 
subcategory of the immune system. 
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5. Organismal Systems
       30min x Day0         30min x 14Days
NES
Adjusted 
p-value
NES
Adjusted 
p-value
5.1. Immune system
Chemokine signaling pathway 1.26 0.155311 1.58 0.013824
Antigen processing and presentation 1.69 0.011978 1.9 0.002066
Toll-like receptor signaling pathway 1.69 0.009981 1.69 0.01011
NOD-like receptor signaling pathway 1.77 0.006418 1.97 0.002066
RIG-I-like receptor signaling pathway 1.81 0.004342 1.49 0.067395
Cytosolic DNA-sensing pathway 1.8 0.008367 2.1 0.002066
C-type lectin receptor signaling pathway 1.23 0.235236 1.52 0.038498
Natural killer cell mediated cytotoxicity 1.04 0.604921 1.54 0.046477
IL-17 signaling pathway 1.32 0.161803 1.69 0.011083
Leukocyte transendothelial migration 1.62 0.024565 1.76 0.006713
5.2. Endocrine system
PPAR signaling pathway -2.48 0.001302 -2.98 0.002066
Insulin signaling pathway -2.08 0.001302 -2.11 0.002066
Progesterone-mediated oocyte maturation 1.25 0.214947 1.6 0.02146
Adipocytokine signaling pathway -1.81 0.005277 -1.94 0.003141
Glucagon signaling pathway -1.97 0.001302 -2.04 0.002066
Regulation of lipolysis in adipocytes -1.93 0.003847 -2.11 0.002066
5.3. Circulatory system
Cardiac muscle contraction -1.99 0.002024 -2.06 0.002066
5.4. Digestive system
Protein digestion and absorption -0.99 0.700604 -1.84 0.007324
Fat digestion and absorption -2.02 0.001302 -2.07 0.007054
Cholesterol metabolism -1.85 0.005638 -2.14 0.002066
5.6. Nervous system
Retrograde endocannabinoid signaling -2.14 0.001302 -1.88 0.003188
5.9. Aging
Longevity regulating pathway -1.64 0.02383 -1.69 0.010281
5.10. Environmental adaptation
Thermogenesis -2.55 0.001302 -2.69 0.00211  
Table 8: Significantly deregulated pathways belonging to KEGG’s main category ‘Organismal Systems’. 
The main category is divided into 10 subcategories (only pathways related to 7 subcategories are significant and 
shown in the table). Significantly deregulated pathways are shown in the table with their respective NES and 
adjusted p-values. Up-regulated (Down-regulated) pathways are indicated by the positive (negative) NES 
coloured in red (green). 
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Albeit related to human diseases, pathways belonging to this main category were summarized 
in table 9 as they could give an overview what effects treatment with blue light are linked to. 
Attention was focused on neurodegenerative diseases like Alzheimer, Parkinson and 
Huntington disease since all of these gene sets, involving mitochondrial pathways related to 
change in ROS or ATP production, were down-regulated as well as oxidative phosphorylation 
pathway seen before.  
Complete list of gene expression results is reported in table 15 of the appendix. 
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6. Human Diseases
       30min x Day0         30min x 14Days
NES
Adjusted 
p-value
NES
Adjusted 
p-value
6.1. Cancers: Overview
Viral carcinogenesis 1.11 0.370221 1.55 0.006713
Chemical carcinogenesis -1.65 0.035832 -1.37 0.1759
Proteoglycans in cancer 1.4 0.022715 1.3 0.114176
MicroRNAs in cancer 1.54 0.01514 1.57 0.00964
Central carbon metabolism in cancer -1.98 0.002024 -1.42 0.114176
6.12. Drug resistance: Antineoplastic
Antifolate resistance 0.85 0.847845 1.7 0.022931
6.2. Cancers: Specific types
Basal cell carcinoma 1.9 0.004206 1.62 0.033739
6.3. Immune diseases
Allograft rejection 1.62 0.053509 1.67 0.026829
Graft versus host disease 1.63 0.050338 1.71 0.02146
6.4. Neurodegenerative diseases
Alzheimer disease -2.52 0.001302 -2.59 0.002084
Parkinson disease -2.7 0.001302 -2.83 0.002066
Huntington disease -2.56 0.001302 -2.42 0.002084
6.7. Endocrine and metabolic diseases
Insulin resistance -1.92 0.001302 -2.06 0.002066
Non-alcoholic fatty liver disease(NAFLD) -2.67 0.001302 -2.84 0.00208
Type I diabetes mellitus 1.59 0.06617 1.76 0.011415
6.8. Infectious diseases: Bacterial
Salmonella infection 1.1 0.486371 1.6 0.03011
6.9. Infectious diseases: Viral
Hepatitis C 1.47 0.027166 1.78 0.002066
Hepatitis B 1.18 0.247718 1.51 0.024494
Measles 1.93 0.005277 1.99 0.002066
Human cytomegalovirus infection 1.29 0.065761 1.53 0.006713
Influenza A 1.84 0.006288 2.11 0.002066
Human T-cell leukemia virus 1 infection 0.89 0.918799 1.53 0.006713
Kaposi sarcoma-associated herpes virus infection 1.15 0.285075 1.6 0.005917
Herpes simplex infection 1.83 0.004592 1.95 0.002066
Epstein-Barr virus infection 1.91 0.00474 2.05 0.002066
Human immunodeficiency virus 1 infection 1.62 0.004952 1.99 0.002066  
Table 9: Significantly de-regulated pathways belonging to KEGG’s main category ‘Human Diseases’. The 
main category is divided into 12 subcategories (only pathways related to 8 subcategories are significant and 
shown in the table). Significantly deregulated pathways are shown in the table with their respective NES and 
adjusted p-values. Up-regulated (Down-regulated) pathways are indicated by the positive (negative) NES 
coloured in red (green). 
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3.6.2 Blue light de-regulated expression of genes involved in adipogenesis and cell 
cycle/cell death. 
A more detailed analysis of individual genes was conducted by analysing three main 
biological processes: adipocyte differentiation, cell cycle / apoptosis. In order to confirm a 
reduced rate of differentiation in blue light treated cells, a pool of genes, known in the 
literature as markers of adipogenesis, has been selected. As shown in figure 30, all the genes 
were strongly down-regulated by blue light at both treatment conditions suggesting a different 
maturation state between the treated cells, partially differentiated (Day0) or undifferentiated 
(14Days), and the controls.  
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Figure 30: Expression changes of a selected pool of genes involved in the adipogenesis. Normalized 
expression is calculated as log of fold change indicating up-regulation (value >0) and down-regulation (value<0) 
of genes. Genes that reached significance with FDR<0.05 are indicated with (*). 
 
In addition the same gene list has been entered in a database of known and predicted protein-
protein interactions. The interactions, including direct (physical) and indirect (functional) 
associations, are shown in figure 31. The genes appeared directly correlated to different 
degrees as if they were at the base of the same mechanism. 
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Figure 31: Protein-protein interactions generated with STRING database.  
 
 
In order to confirm that the aforementioned decrease in lipid accumulation was mediated by 
decreasing adipogenesis and not by lipolysis activation, the gene expression of lipolytic 
enzymes hormone sensitive lipase (Lipe) and the lipogenic enzyme lipoprotein lipase (Lpl) 
was analysed. Also leptin expression was taken into account as marker of lipid accumulation. 
All three genes were down-regulated by blue light treatment as shown in figure 32. 
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Figure 32: Expression changes of markers of lipid accumulation Normalized expression is calculated as log 
of fold change indicating up-regulation (value >0) and down-regulation (value<0) of genes. Genes that reached 
significance with FDR<0.05 are indicated with (*). 
 
Secondly, genes involved in cell cycle have been selected. A similar trend was observed for 
both treatments with a pronounced de-regulation in daily treatments. According to gene 
expression analysis the levels of cyclins and related dependent-kinases (CDKs) revealed an 
increase especially in genes of S and G2 phases. Also genes involved in cell cycle inhibition 
(Cdkn1a), repairing systems or apoptosis (p53 and Wee1), were up-regulated following blue 
light chronic exposure (Figure 33).  
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Figure 33: Expression changes of a selected pool of genes involved in the cell cycle. Normalized expression 
is calculated as log of fold change indicating up-regulation (value >0) and down-regulation (value<0) of genes. 
Genes that reached significance with FDR<0.05 are indicated with (*). 
 
 
3.6.3 Gene expression analysis 2° set-up: Blue light irradiation on mature adipocytes 
Gene expression data have been analyzed as before. RNA seq screneed 24421 genes in total, 
745 were significantly expressed (FDR <0.05) in treated samples. The number of de-regulated 
genes has been really low if compared to the results obtained on maturing preadipocytes. In 
the previous tests were shown no evident effects on irradiated samples and also gene 
expression followed the same trend. However, in relation to the blue light doses, differentially 
adjusted genes were increased in total number from 276 de-regulated genes after 30 minutes a 
day (21.6 J/cm
2
), to 718 genes after 60 minutes a day (43.2 J/cm
2
). 249 genes were triggered 
commonly (Figure 34). 
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Figure 34: Venn diagram showing the number of significantly (FDR<0,05) commonly or differentially 
expressed genes in differentiated adipocytes following 30 min (21.6 J/cm
2
) or 60min (43.2 J/cm
2
) blue light 
doses.  
 
 
In the table 10 the number of up- and down-regulated genes is given. De-regulated genes have 
increased by the dose used and a majority of up-regulated genes at both doses was found.  
 
    Treatment group     Significantly differentially expressed genes
Irradiation time   Down-regulated genes Up-regulated genes
30min x 7Days 81 195
60min x 7Days 301 417  
Table 10: Number of significantly up and down-regulated genes differentially expressed in differentiated 
adipocytes following 30 min (21.6 J/cm
2
) or 60min (43.2 J/cm
2
) blue light doses.  
 
Thereafter, Gene Set Enrichment Analysis (GSEA) was performed using Kyoto Encyclopedia 
of Genes and Genomes (KEGG) database to transform the list of individual genes into a set of 
pathways. As before a Normalized Enrichment Scores (NES) was used to indicate the 
distribution of the pathway within the list. Negative or positive NES indicates down- or up-
regulated pathways. Table 11 lists the number of de-regulated KEGG pathways for both 
treatment conditions. Starting from a total gene set number equal to 281, the number of down-
regulated pathways for 30min a day irradiation was lower than the up-regulated pathways. Of 
these de-regulated pathways one fifth was significant with a p-value < 0.05 and, even less if 
an adjusted p-value (FDR) with the same cut-off was considered. A same trend occurred as a 
result of 60 minutes irradiation; up-regulated pathways prevailed over down-regulated 
pathways. Also in this case the number of significant pathways (p-value <0.05) was 
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drastically reduced without departing in large numbers from the highly significant ones (FDR 
<0.05). 
 
Treatment group 30min x 7Days 60min x 7Days
De-regulated pathways 307 307
Up-regulated pathways 177 192
with nominal p-value < 0.05 41 46
with nominal p-value < 0.01 21 25
with adjusted p-value (FDR) <0.05 21 15
Down-regulated pathways 130 116
with nominal p-value < 0.05 23 27
with nominal p-value < 0.01 20 17
with adjusted p-value (FDR) <0.05 18 17  
Table 11: Number of differentially expressed KEGG pathways in differentiated adipocytes following 30 
min (21.6 J/cm
2
) or 60min (43.2 J/cm
2
) blue light doses. Starting from an overall gene set number of 281, total 
numbers of up- or down-regulated pathways are shown. In addition the number of significantly enriched 
pathways is listed for different significance levels at nominal p- value < 0,05 or < 0,01 and at adjusted p-value 
(FDR) <0,05. 
 
 
Only de-regulated pathways with an adjusted p-value (FDR) ≤ 0.05 have been taken into 
account for the subsequent analysis. As shown in figure 35 pathways were sorted into 6 main 
KEGG categories. For both irradiation doses most of down-regulated pathways belong to the 
Metabolism category with a similar behaviour also for the other categories in both treatments. 
In contrast, up-regulation was more pronounced in Human diseases category. 
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Figure 35: (A) Distribution of significantly enriched pathways (FDR < 0.05) sorted by main categories of 
KEGG. Groups are formed by the respective doses/irradiation times. The numbers around the pie charts 
indicate the number of deregulated pathways contained in each category. (B) Comparison of significant 
pathway list with NES < 0 and (C) NES > 0 at different irradiation time. 
 
Table 12 lists de-regulated significant pathways of the first main category: Metabolism. The 
general metabolism seems to be down-regulated by the blue light. Two of the main cellular 
processes, the citrate cycle and oxidative phosphorylation, showed reduced activity in 
irradiated samples. Up-regulated were the pathways involved in detoxification systems such 
as cytochrome P450 and Glutathione metabolism. 
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Metabolism
      30min x 7Days         30min x 7Days
NES
Adjusted 
p-value
NES
Adjusted 
p-value
1.0 Global and overview maps
Metabolic pathways -1.27 0.006341 -1.41 0.004806
Biosynthesis of amino acids -1.59 0.020963 -1.68 0.015953
Carbon metabolism -1.52 0.026926 -1.56 0.017163
2-Oxocarboxylic acid metabolism -1.76 0.022223 -1.79 0.019425
1.1. Carbohydrate metabolism
Citrate cycle (TCA cycle) -2.05 0.004753 -2.02 0.004806
Propanoate metabolism -1.85 0.010783 -1.88 0.004806
Amino sugar and nucleotide sugar metabolism -1.33 0.27152 -1.67 0.026506
Inositol phosphate metabolism -1.77 0.009464 -1.11 0.477763
1.2. Energy metabolism
Oxidative phosphorylation -1.74 0.009464 -1.91 0.004806
1.6. Metabolism of other amino acids
Glutathione metabolism 1.75 0.009869 1.8 0.009505
1.11. Xenobiotics biodegradation and metabolism
Metabolism of xenobiotics by cytochrome P450 1.87 0.004753 1.9 0.007585
Drug metabolism (cytochrome P450) 1.89 0.004753 1.91 0.007585
Drug metabolism (other enzymes) 1.79 0.004753 1.72 0.009505  
Table 12: Significantly de-regulated pathways belonging to KEGG’s main category ‘Metabolism’. The 
main category is divided into 13 subcategories in total (only pathways related to 5 subcategories are significant 
and shown in the table). Significantly deregulated pathways are shown in the table with their respective NES and 
adjusted p-values. Down-regulated (Up-regulated) pathways are indicated by the negative (positive) NES 
coloured in green (red). 
 
 
Few pathways have reached statistical significance in the other categories. Among these Jak-
Stat signalling, cytokine-cytokine receptor interaction and thermogenesis pathways that could 
be involved in important mechanisms in the adipose tissue (Table 13). 
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2. Genetic Information Processing
      30min x 7Days         30min x 7Days
NES
Adjusted 
p-value
NES
Adjusted 
p-value
2.2. Translation
Aminoacyl-tRNA biosynthesis -1.78 0.017661 -1.81 0.015953
2.3. Folding, sorting and degradation
Protein processing in endoplasmic reticulum -2.07 0.004753 -2.21 0.004806
Protein export -2.01 0.004753 -2.06 0.004806
3. Environmental Information Processing
3.2. Signal transduction
JAK-STAT signaling pathway 1.54 0.020015 1.57 0.011737
Phospholipase D signaling pathway -1.55 0.020361 -1.18 0.335519
Phosphatidylinositol signaling system -1.74 0.007398 -1.1 0.48188
3.3. Signaling molecules and interaction
Cytokine-cytokine receptor interaction 1.54 0.009464 1.6 0.004806
Neuroactive ligand-receptor interaction 1.41 0.022223 1.47 0.011737
4. Cellular Processes
4.1. Transport and catabolism
Endocytosis -1.35 0.051984 -1.4 0.038663
5. Organismal Systems
5.1. Immune system
Cytosolic DNA-sensing pathway 1.52 0.097055 1.67 0.030948
Complement and coagulation cascades 1.73 0.004753 1.57 0.055223
Hematopoietic cell lineage 1.6 0.026416 1.36 0.156005
5.10. Environmental adaptation
Thermogenesis -1.42 0.031242 -1.59 0.007572  
Table 13: Significantly de-regulated pathways belonging to KEGG’s main category ‘Genetic information 
processing’, “Signal transduction”, “Cellular processes”, “Organismal systems”. Significantly deregulated 
pathways are shown in the table with their respective NES and adjusted p-values. Down-regulated (Up-
regulated) pathways are indicated by the negative (positive) NES coloured in green (red). 
 
In the table 14 are shown Human diseases pathways. Also in this case neurodegenerative 
diseases appeared down-regulated according to the theory of reduction in oxidative 
phosphorylation. 
Complete list of gene expression results is reported in table 16 of the appendix. 
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6. Human Diseases
      30min x 7Days         30min x 7Days
NES
Adjusted 
p-value
NES
Adjusted 
p-value
6.1. Cancers: Overview
Chemical carcinogenesis 1.97 0.004753 1.89 0.004806
MicroRNAs in cancer 1.02 0.702703 1.5 0.01406
6.2. Cancers: Specific types
Acute myeloid leukemia 1.65 0.022223 1.58 0.060973
6.3. Immune diseases
Autoimmune thyroid disease 1.92 0.004753 1.57 0.060894
Graft-versus-host disease 1.85 0.004753 1.57 0.071698
Allograft rejection 1.78 0.00676 1.57 0.072807
6.4. Neurodegenerative diseases
Huntington disease -1.73 0.004753 -1.83 0.004806
Alzheimer disease -1.98 0.004753 -2.11 0.004806
Parkinson disease -1.76 0.007398 -1.96 0.004806
6.6. Cardiovascular diseases
Fluid shear stress and atherosclerosis 1.56 0.021578 1.39 0.103312
6.7. Endocrine and metabolic diseases
Non-alcoholic fatty liver disease (NAFLD) -1.6 0.014312 -1.71 0.004806
Type I diabetes mellitus 1.63 0.026926 1.39 0.186243
6.8. Infectious diseases: Bacterial
Staphylococcus aureus infection 2.13 0.004753 1.78 0.004806
6.9. Infectious diseases: Viral
Epstein-Barr virus infection 1.69 0.004753 1.62 0.004806
Hepatitis C 1.46 0.041657 1.62 0.009505
Herpes simplex infection 1.64 0.004753 1.56 0.009505
Influenza A 1.48 0.031242 1.44 0.060894
6.12. Drug resistance: Antineoplastic
Platinum drug resistance 1.46 0.107209 1.66 0.030098  
Table 14: Significantly de-regulated pathways belonging to KEGG’s main category ‘Human Diseases’. 
The main category is divided into 12 subcategories (only pathways related to 10 subcategories are significant 
and shown in the table). Significantly deregulated pathways are shown in the table with their respective NES and 
adjusted p-values. Up-regulated (Down-regulated) pathways are indicated by the positive (negative) NES 
coloured in red (green). 
 
 
3.6.4 Blue light did not affect lipolysis in mature adipocytes. 
In order to evaluate blue light effects on the lipolysis, the expression of genes involved in this 
process was analysed. To the expression analysis of leptin, hormone sensitive lipase (LIPE) 
and lipoprotein lipase (LPL) genes previous considered, also monoglyceride lipase (Mgll) and 
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adipose.tissue trygliceride lipase (Pnpla2) were added. Although the expression of some 
genes was reduced or even downgraded after 60-minute treatments, this change was not 
statistically significant. (Figure 36). 
 
Figure 36: Expression changes of markers of lipolysis and lipogenesis Normalized expression is calculated as 
log of fold change indicating up-regulation (value >0) and down-regulation (value<0) of genes. Genes did not 
reach significance. 
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4 Discussion 
4.1 Effects of single or multiple exposures of blue light at 21.6 J/cm2 dosage during 
adipocyte differentiation. 
The interest in PBM has rapidly grown for medical application requiring reduction of pain, 
inflammation and stimulation of healing and tissue regeneration. Stimulatory or inhibitory 
effects on biological processes depend on the wavelength, energy dose and cell type. 
Traditionally red (600–700 nm) and near-infrared (NIR, 780–1100 nm) wavelengths were 
employed in many studies and their effects have been better characterized. However evidence 
is mounting that shorter visible wavelengths such as blue and green light can also have 
photobiomodulatory effects showing distinct differences from those generally observed with 
red/NIR light. One of the limitation in the use of these short wavelengths is represented by the 
low penetrating capacity. It has been demonstrated that in spite of the fact that most of 
sunlight in the visible spectrum does not pass through the skin, approximately 1–5% of 
blue/green light is able to penetrate it to varying depths proportional to increasing wavelength 
and intensity and reach the underlying subcutaneous white adipose tissue (scWAT). The 
purpose of this study has been to improve the knowledge regarding the effects of blue light by 
evaluating the response of 3T3-L1 cells to 453nm blue light. On the basis of biphasic dose-
response curves, Schulz’s law8, 9 specifies that therapeutically applied energy must be of the 
proper intensity per unit of time to stimulate the desired physiological response. Low energies 
evoke stimulation reaching their maximum following even stronger stimuli; instead, high 
energies result in inhibitory effects. In order to use blue light in body-shaping or disease 
treatments such as obesity or lipid dysfunctions, high blue light doses were applied, 21.6 
J/cm2 and 43.2 J/cm2, in a different number of treatments for each set-ups. Photomodulatory 
effects were investigated during and after differentiation process using 3T3-L1 cells as model 
of adipose tissue. Various stainings were performed to evaluate variations in lipid 
accumulation while XTT, ATP and BrdU assays were used to follow changes on metabolism 
and proliferation. In addition, to elucidate which genes and signalling pathways were 
commonly or differentially expressed after different irradiation doses, gene expression 
analyses were performed. 
According to the protocol illustrated by Zebisch et al
74
, 3T3-L1 preadipocytes have been 
differentiated. Setting a constant irradiance value of 12 mW/cm
2
 at plate surface, single or 
multiple blue light irradiations were applied on cells during the differentiation process using a 
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dose of 21.6 J/cm
2
 equal to an irradiation time of 30 minutes performed on the first day 
(Day0) or during all 14 days of differentiation. Using Oil Red O staining and related 
quantification, changes in lipid accumulation were investigated. Single irradiation on Day0 
has shown a reduction of 17% of lipid amount while a reduction of 38% was reached with 
daily irradiation with the same dose (Figure 15). Cells treated for 14 days appeared poorly 
differentiated under the microscope when compared to one-day treatment or to the controls. 
The reduction in lipid accumulation could be due to reduced adipogenesis. These data seem to 
be supported by gene expression results which showed a strongly down-regulated lipid 
metabolism in relation to the number of treatments received. A more detailed analysis 
presented a reduced expression of a selected group of genes involved in the differentiation 
(Figure 30). PPAR-γ and several members of the C/EBP family of transcription factors 
participate in a signalling cascade that culminates in the transcriptional activation of genes 
involved in the production of the adipocyte phenotype. The expression of these markers of 
adipogenesis was found strongly decreased after multiple treatments although the effects 
already occur on Day0 long-lasting up to two weeks. Although there is still no evidence in the 
literature on the effects of blue light on 3T3-L1 differentiation, the results of this study are 
partially in line with Lee et al.
75
 who showed how ultraviolet A (UVA) irradiation inhibits 
adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells. In their 
findings effects are mediated by expression of KLF2 which operates as an anti-adipogenic 
factor binding and repressing the PPAR-γ promoter. Although they reported reduced mRNA 
levels of PPAR-γ and C/EBP-α after UVA irradiation, C/EBP-β and δ, the upstream 
regulators of PPAR-γ and C/EBP α, have not undergone variations in expression. 
In the present study all the aforementioned genes were down-regulated by blue light 
irradiation suggesting an inhibitory mechanism independent of KLF2 action. Ju Kim et al.
76
 
and Wen-Hwa Li et al.
77
 observed increased levels of TNF-alpha and several cytokines (IL-
11, IL-1a, IL-6, IL-8) following chronic UV irradiation that leads to inhibition of 
preadipocytes differentiation into mature adipocytes by selective inhibition of expression of 
the adipogenic transcription factors, i.e., peroxisome proliferator-activated receptor gamma 
(PPAR-g) and CCAAT / enhancer binding protein alpha (CERB-a), and lipogenesis. 
Consistent with those data, despite TNF-alpha expression was not detected by RNA 
sequencing following blue light exposure of 3T3-L1, an activation of TNF-alpha signalling 
was found for both irradiation times while IL-6, IL-11 levels were enriched only following 
daily exposures. This inflammatory process could suggest a possible mechanism of inhibition 
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of differentiation. In addition, AMPK protein is demonstrated to be activated in adipose tissue 
under inflammatory conditions in order to inhibit this condition
78
. Blue light treatments 
tended to lower AMPK transcription, especially in the α1-catalytic subunit, suggesting an 
amplified inflammation. AMPK activation is also involved in numerous mechanisms such as 
lipolysis, lipogenesis and adipogenesis. These processes have been found deregulated in 3T3-
L1 cells irradiated with blue light assuming mechanisms independent of AMPK activity, 
although little is known about the inhibition of this kinase and nothing is reported in relation 
to blue light exposure. 
The promotion of an undifferentiated phenotype is due to changes in transcription and gene 
expression that inevitably leads to alterations in cell metabolism. Using XTT cell viability 
assay mitochondrial activity and cell viability were investigated at the end of the 
differentiation process directly after the last irradiation or 24h later. Single or multiple 
irradiations did not show a pronounced alteration of metabolism that in both conditions 
decreased about 10% compared to the untreated samples without recovering this condition 
after 24h (Figure 18). Following exposure to several blue light sources in normal and cancer 
cells, different effects were obtained in Wataha et al
79
 studies. They estimated cell energy 
consumption by population doubling time and cell survival and growth by succinate 
dehydrogenase (SDH) activity. Cells with a short doubling time, such as aneuploid mouse 
lung fibroblasts (Balb/c), revealed a constant suppression of SDH activity while slower-
growing cells reacted differently. Indeed blue light exposure of human gingival fibroblasts 
(HGF) resulted in a transient suppression of SDH activity by 30% at 24 hours, attenuated 
within the next 48 hours. Based on these cell type-specific responses, population doubling 
time and related energy consumption mediate differential effects suggesting besides that 
rapidly dividing cells are more sensitive to irradiation. With a population doubling time of 
25.7 ± 1.3 hours, 3T3-L1 cells used in this study are in midway between a fast-growing and a 
slow-growing cell line showing moderate effects on viability and mitochondrial activity. 
 
In literature strong evidence exists that LLLT acts on mitochondria which, containing an high 
degree of cytochromes and flavins, are logical mediators of the effects of blue light in 
increased ATP
80
 and ROS production and in the induction of transcription factors
81
. For this 
reason modulation of mitochondrial function was evaluated assessing the ATP levels in light-
treated and untreated cells. Although most of the studies reported elevated ATP levels after 
laser / LED treatment, ATP was diminished directly after blue light irradiation in 
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differentiating 3T3-L1 cells in a dose dependent manner. A slight recovery was recorded after 
24 hours. (Figure 20). Collected outcomes are in line with Wang et al
82
 studies on adipose-
derived stem cells (ASCs), describing lower ATP contents after blue/green light opposite to a 
biphasic increase for red/NIR.  
A rise in the AMP/ATP ratio is typical of a metabolic stress condition. In several 
neurodegenerative diseases mitochondria play a crucial role
83
. In this context pathways like 
Alzheimer, Parkinson and Huntington disease were found down-regulated in both conditions. 
In detail, oxidative phosphorylation and the expression of genes like NDUFA1, SDBH, 
CYC1, and ATP5A1 encoding subunits of respiratory chain complexes I-V were significantly 
lower in single and multiple irradiated samples compared to the controls. The reduced activity 
of these complexes could lead to a compromised energy metabolism by blocking the transfer 
of electrons within the respiratory chain which may result in reduced susceptibility to 
apoptosis
84
. In addition, SLC25A4, which encodes for the ADP/ATP carrier subunit through 
the mitochondrial membrane, was found significantly down-regulated, favouring an 
unbalanced energy state. 
 
The mitochondrial theory of ageing
85, 86
 argues that reduction in ATP synthesis and increase 
in ROS production are the consequence of a progressive accumulation of mutations or 
environmental influences on mitochondria or their DNA (mtDNA) resulting in a thus driving 
oxidative stress, inflammation and cell loss. Based on this interplay between down regulation 
of ATP and up regulation of ROS in oxidatively stressed cells, also intracellular ROS levels 
were assessed. ROS levels were measured spectrophotometrically using an intracellular 
fluorescent dye, DCFDA, that measures hydroxyl, peroxyl and other reactive oxygen species 
(ROS) activity within the cell. Unexpectedly a high standard deviation was recorded when the 
test was performed 14 days after last irradiation for irradiated samples at Day0, complicating 
data interpretation (Figure 25). ROS levels similar or equal to controls were expected. The 
high standard deviation probably is due to the instability of the probe or the capability of the 
intermediate radical, DCF•−, formed from the one-electron oxidation of DCFH, to rapidly 
react with O
2
 to form superoxide. Instead dosage of 14 x 26.1 J/cm
2
 did not show an increase 
in ROS levels that were even lower than untreated controls. Furthermore, since the DCFDA is 
a cytoplasmic dye probably it is not able to give a correct estimation of the general ROS 
content within the mitochondria. Some reactive oxygen species, such as superoxide, are 
strongly charged and do not cross the mitochondrial membrane
87
, thus remaining confined in 
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the organelle, and are probably unable to react with the DCFDA. The ROS content may have 
been therefore underestimated. Detailed analysis of genes encoding ROS metabolism 
enzymes confirmed the ROS increase though was not revealed by DCFDA assay. Poglio et 
al.
88
 studies showed how ionizing radiations could decrease gene expression ROS metabolism 
enzymes improving their harmful activity. Similarly, blue light irradiation leads to a reduction 
in detoxifying enzymes such as SOD2. Aconitase, a mitochondrial enzyme particularly 
sensible to ROS activity, is also reduced while NADPH oxidase, major source of reactive 
species, increased its expression levels following irradiation. 
Based on gene expression levels, KEGG pathways related to repair mechanisms were found 
up-regulated. While a single irradiation has shown significance only in “nucleotide excision 
repair” pathway, multiple irradiations were significant also for “base excision repair” and 
“mismatch repair” which are ascribed to VIS or UV irradiation. In contrast Taoufik et al.89 did 
not observe DNA double strand breaks in primary human gingival fibroblasts even treated 
with higher blue light doses. Besides, Mignon et al.
90
 have found several repair pathways 
down-regulated following blue light exposure of primary reticular fibroblasts. In contrast 
Yuan et al.
41
 described a high percentage of damaged DNA in bone marrow-derived 
mesenchymal stem cells (BMSCs). 
KEGG pathway related to apoptosis showed significant up-regulation after 14 x 21.6 j/cm
2
 
dosage. However a detailed analysis of caspases or other pro-apoptotic genes did not reveal 
an increase in the expression. Though some pro-apoptotic factors like Bid and Bax showed a 
slight and statistical significant increase, the gene expression of XIAP, AIF-1 CASP3 CASP9, 
and Cytochrome-C, involved in apoptotic extrinsic pathway, were down or not significantly 
expressed. Literature reported that, even in the absence of caspase activity, cells can succumb 
to a slower form of death termed caspase independent cell death (CICD). CICD ensues when 
a signal that normally induces apoptosis fails in caspase activation ensuring a failsafe 
mechanism that leads to cell death. Chautan et al.
91
 reported that CICD is not a secondary 
mechanism but occurs for up to 10% of cells thus representing the major cell death modality. 
Moreover animal studies reported how in Bax/Bak deficient mice and Apaf-1 deficient mice 
CICD can substitute apoptosis during development
92
. Even if CICD is a caspase independent 
mechanism it often shares common characteristics with apoptosis, including signalling 
pathways that are critical for both forms of death, such as mitochondrial outer membrane 
permeabilization (MOMP). MOMP is often deregulated in cancer and can be initiated by a 
range of physical, chemical and pathophysiological stimuli including lysosomal/ER stress, 
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DNA damage, metabolic stress, cellular stress caused by ionizing radiation, heat, hypoxia, 
cytokine deprivation and chemotherapeutic drugs. How CICD can occurs following MOMP is 
still unknown and varies in a cell-type dependent manner. The main models by which MOMP 
can bring about CICD are either through a general decline in mitochondrial function and/or 
through the release of mitochondrial proteins such as AIF-1 that can actively induce CICD in 
some settings. Mitochondria have various critical cellular functions, the most important is the 
generation of ATP through the process of aerobic respiration. Under apoptotic conditions, 
caspase-3 dependent cleavage of p75 of mitochondrial respiratory chain complex I leads to 
disruption of electron transport, loss of mitochondrial membrane potential (Δψm) and 
reduction of ATP levels
93
. However, under conditions of CICD, mitochondria gradually lose 
Δψm independently of p75 cleavage94. Why this occurs is not clear but one reason may be a 
gradual release of respiratory chain components from the mitochondria following MOMP. 
Gradual loss of Δψm consequently leads to the loss of ATP generation. According to these 
lines, cells that undergo CICD present a rapid reduction in mitochondrial respiratory 
complexes-I and IV. Furthermore, given the important role that AIF-1 has in maintaining 
respiratory complex I function, loss or low levels, can also promote and sustain mitochondrial 
dysfunction. This condition leads to metabolic catastrophe and at the end to cell death. In line 
with a reduction of ATP and rise in DNA repair pathways, CICD could explain the possible 
reduction in cell number highlighted by Hoechst staining. Besides, also p53 signaling was up-
regulated as well as ATM. These proteins positively influence the Bid/Bax expression to 
promote the MOMP. Moreover ATM can directly phosphorylate p53 inducing the activation 
of DNA repair proteins and cell growth arrest.  
 
The reduction in metabolic activity, revealed by XTT and ATP assays following blue light, 
cannot be directly correlated to cell proliferation rate. Using BrdU ELISA, DNA synthesis 
was studied during 14 days of differentiation. A continuous decline in DNA synthesis was 
recorded (Figure 24), accompanied by a reduction in cell count performed with Hoechst 
staining (Figure 22). In line with this data, Liebmann et al.
39
 have reported a lower 
proliferation in keratinocytes irradiated with blue light at 453nm though attributable to 
differentiation induction. Shreder et al.
95
 have tested the effects of X-rays on Simpson-Golabi-
Behmel Syndrome (SGBS) preadipocytes and human primary preadipocytes ascertaining 
decreased proliferation rate and clonogenic capacity of both cell strains. Thus, the 
regenerative potential of irradiated preadipocytes was reduced. Furthermore, the authors 
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claimed that the weak apoptotic response after preadipocytes irradiation indicated that the 
reduction in proliferation rate was likely a result of cell cycle arrest rather than cell death. The 
effects of blue light during 3T3-L1 differentiation remain still unknown. In this context 
KEGG’s cell cycle pathway was up-regulated with both irradiation times. Assuming a 
possible delay or arrest in cell cycle process the expression of genes involved were analysed 
in detail. This pathway considers both cyclin expression and DNA damage repair systems. 
Following multiple irradiations the oncogene c-myc was significantly up-regulated. It has 
been proven to be a powerful activator of the cell cycle in serum starved 3T3-L1 cells
96
 
Moreover overexpression of c-myc was shown to inhibit adipogenesis in 3T3-L1 cells 
possibly by precluding the entry into a distinct pre-differentiation stage in G0/G1, a 
fundamental condition for terminal differentiation
97
. Although this is an important factor, 
mere overexpression of c-myc is not sufficient for the progression in the cell cycle. The cell 
cycle process is based on a series of phosphorylation/de-phosphorylation reactions regulating 
the balance between promoters and inhibitors. The cyclin-cdk complexes form holoenzymes 
that phosphorylate the proteins of the Retinoblastoma family (pRb, p107 and p130) which act 
at different passages of the cell cycle. Phosphorylation levels are dependent on the cycle 
phase; for example in exceeding the restriction point of G1 phase, Rb is phosphorylated by 
the Cyclin D/cdk4-6 activated complex. The hypophosphorylated forms dominate in G0 and 
in the early G1 phase, while the more phosphorylated forms are present in the S phase, G2 
and M. Further levels of phosphorylation may appear dependent on the type of cell 
considered. When Rb is phosphorylated, it loses affinity for the E2F protein which acquires 
the ability to activate the transcription of genes involved in the progression of the cycle from 
one phase to the next. In this study Rb expression was found significantly low in irradiated 
samples during differentiation. The reduced Rb expression probably is similar to the effects of 
mutant Rb, thus preventing E2F-mediated transcription. A common aspect of proteins linked 
to pRb and tumour suppressor genes such as p53 is their ability to inhibit cell proliferation. In 
addition, studies of Reichert et al.
98
 have shown changes in cyclins levels depending on stages 
of adipogenesis and addition or different percentage of serum. Taking these variables into 
consideration, the analysis in relation to treatments with blue light becomes even more 
complex. Although the levels of the complex Cyclin D/Cdk4-6 showed an increase, the 
negative trend of the Cyclin E/Cdk2 complex, combined with the down regulation of the Rb 
gene, has been supposed to lead to a cellular delay in G1/S phase. A second delay or arrest 
may occur in phase G2. Since phase G2 provides the time for proofreading and packaging the 
replicated DNA prior to cell division, its prolongation may indicate an accumulation of 
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replication errors, which keeps the 3T3-L1 cells irradiated at checkpoint G2 / M preventing 
them from proceeding through the cell cycle. As discussed earlier, the path of mismatch 
repairs, activated in response to replication errors, has been greatly enhanced. In addition, 
several genes involved in network reporting of DNA damage response were found positively 
expressed. Indeed, the activation of Chk1 mediated by the ATM/ATR system that recognizes 
single-stranded DNA (ssDNA) can be the result of UV-induced damage, replication stress and 
cross-linking between strands
99, 100
. In addition, activated Chk1 promotes ubiquitination and 
degradation of Cdc25 phosphatase, activates repair factors, such as cellular nuclear antigen 
proliferation (PCNA) or Rad51, and interacts with many downstream effectors such as Wee1 
kinase and PLK1. This complex signalling results in cell cycle stoppage and DNA repair. In 
addition, Chk1 plays a role in the control point of the spindle during mitosis interacting with 
the proteins of the Aurora A kinase and Aurora B kinase spindle group.  
The cells are maintained in the G2 phase until they are ready to enter the mitosis phase. In this 
state the cells can repair the DNA and recover or die if the DNA damage is irreversible
101
. 
The expression of all these genes has been enriched following consecutive light treatments 
with 21.6 J/cm
2
, showing the same tendency and in many cases were significant already after 
a single irradiation with long-lasting effects. Despite the presence of persistent DNA damage, 
cells can enter mitosis following a sustained checkpoint-imposed cell cycle arrest. This ability 
is called checkpoint adaptation. A checkpoint-regulated protein, Claspin, was increased in 
expression already after a single irradiation. Required for efficient DNA replication during a 
normal S phase, Claspin can mediates both activation of Chk1 and the inactivation after a 
prolonged G2/M arrest, permitting the entry into mitosis. Cells that enter in mitosis following 
adaptation will arrest in metaphase that can lead to “mitotic catastrophe”102. This adaptation 
represents an alternative elimination process of cells with unrepairable damage
103
.  
The lower rate of DNA synthesis, cell count and the latter hypothesis of arrest in G2 / M 
phase suggested deleterious effects of high doses of blue light during 3T3-L1 cell 
differentiation. 
 
4.2 Effects of multiple exposures of blue light at dose of 21.6 J/cm2 and 43.3 J/cm2 on 
mature adipocytes 
Since mature adipocytes constitute one-third of adipose tissue, blue light effects were tested 
after complete 3T3-L1 differentiation. Multiple blue light irradiations were applied on cells 
for 7 days using a dose of 21.6 J/cm
2
 equal to an irradiation time of 30 minutes and 43.2 J/cm
2
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equal to an irradiation time of 60 minutes. Evaluation of lipid accumulation was performed as 
before using Oil Red O staining and related quantification. Both fluences showed a slight and 
insignificant increase in the lipid amount compared to dark controls (Figure 17). Thus, blue 
light irradiation did not affect the number of lipid droplets and lipid amount. Gene expression 
analysis was consistent with Oil Red O staining results. First we investigated whether 
adipogenic markers were affected by 453nm blue light in differentiated adipocytes. No 
differences were found between treated and untreated. Choi et al.
104
 have tested the effects of 
several wavelengths in the visible light between 410nm and 690nm observing that only 
irradiation at 590nm enhance the breakdown of lipid droplets. Probably the wavelength of 
453nm chosen for this study was not suitable to induce an activation of lipolysis or reduction 
of lipid droplets. 
 
XTT and ATP assays were performed in order to evaluate metabolic activity and 
mitochondria status. While XTT showed a slight decrease directly after 30 min of irradiation 
that did not vanish after 24h, no significant changes were recorded after 60 min of treatment 
(Figure 19). Instead, a different trend was observed for the ATP levels where the magnitude 
of the increase was dependent on the dose of radiations. While after 24 hours the ATP levels 
were comparable to controls in samples exposed 30 minutes a day to blue light, the levels 
remained still high after 60 minutes exposures (Figure 21). Blue light stimulated mitochondria 
in adipocytes that led to an increase in ATP synthesis that was not enough to stimulate 
cytoplasmic lipase activity. All studies reported lipolysis or fat reduction after LLLT 
treatment used higher wavelengths from 635 nm upwards
105
. 
 
Compared to irradiated preadipocytes, differentiated adipocytes appear less sensible to 
radiation. Despite a reduction in oxidative phosphorylation for both fluences, mitochondria 
and respiratory chain were not completely  damaged since were still able to produce ATP. 
Also ROS levels did not increase following irradiation (Figure 26) and genes involved in 
detoxification systems were not significantly deregulated in treated cells.  
 
Cell counting with Hoechst staining also has not shown differences between treated and 
controls. This data could be explained with the adipocyte's characteristic of being a terminally 
differentiated cell. Once completely differentiated, adipocytes can increase or decrease in size 
but not in number. The number of adipocytes increases only in severe obesity in which 
Discussion 
72 
 
paracrine/autocrine factors secreted from the various cells within adipose tissue stimulate 
preadipocytes to form new mature cells
106
. In line, also gene expression did not reflect a 
significant de-regulation in cell cycle or apoptosis pathways. Thus, blue light seems not to 
affect proliferation nor induce apoptosis in mature adipocytes. 
Also genes involved in JAK-STAT or Cytochrome p450 up-regulated pathways did not show 
significant changes. This difference between NES of KEGG pathway and expression of a 
gene is due to a different system analysis. Therefore a gene can be up-regulated in relation to 
the other genes considered in the same pathway (KEGG analysis) but it can be down 
regulated or not significantly expressed if the absolute value of expression of that gene is 
considered.  
 
4.3 Conclusions 
In conclusion, this preliminary in vitro study showed the different effects at transcriptional 
and metabolic level during and after adipocyte differentiation. During differentiation cells 
were more responsive to irradiation, especially in the early stages. This is probably due to a 
series of processes that are triggered in the first 48 hours from induction in a phase known as 
mitotic clonal expansion (MCE). During this period the cells rearrange their morphology and 
trigger the transcription of genes essential for the adipocyte phenotype. A single irradiation at 
a dose of 21.6 j/cm
2
 at the first day of induction a partial reduction in differentiation was seen 
evidenced by a reduced lipid amount and a downregulation of adipogenic markers. Slight 
metabolic effects were observed with a reduction in proliferation and activation of apoptotic 
processes induced by damage to DNA and biological systems, albeit with moderate effects. 
Cells are able to partially recover by triggering mechanisms of repair that inevitably lead to a 
delay in the cell cycle. The cells that are repaired from the damage continue in proliferation 
and differentiation. Pronounced effects occur as a result of multiple irradiations. After two 
weeks of treatments the cells interrupted differentiation and are morphologically similar to 
fibroblasts. Continued exposure to blue light causes an increase in ROS levels which are not 
attenuated by the detoxification system. Chronic damage occurs and the proliferation/death 
ratio shifts in favour of the latter following a prolonged arrest in the G2/M phase, confirmed 
by overexpression of genes involved in mechanisms of damage repair. 
Mature adipocytes, on the other hand, did not show significant metabolic or transcriptional 
changes although a more pronounced trend was obtained at higher doses. 
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To date, blue light seems to be able to treat conditions of adipocyte hyperplasia but not 
hypertrophy, although taking into account cellular damage. 
In vitro results alone are not sufficient to promote or reject blue light as a therapeutic means 
in the treatment of diseases involving dysfunction of adipose tissue. Further studies are 
needed especially in vivo where the effects could be systemic due to a cross-talk between 
different cells lines present in higher layers, such as the skin. These cell lines can be detected 
in fibroblasts and keratinocytes that, being more accustomed to exposure to radiation, i.e. 
solar radiations, can activate modulatory mechanisms even in the layers of the hypodermis 
involving the adipocytes. 
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5 Summary 
Phototherapy was applied to treat medical conditions since 3,500 years, when the ancient 
Egyptians and Indians used sunlight to treat various diseases. It was only with the invention of 
electric light in the late 19th century that an alternative emerged. From that time on, the use of 
phototherapy in the medical field grew, techniques were perfected and developed and 
eventually gained widespread acceptance. To date, over 2000 scientific articles have been 
published in PubMed focusing on the various physiological effects of red and NIR radiation. 
These wavelengths of light have been shown to penetrate through human tissues and to 
locally and systematically influence cell metabolism, cell signalling, inflammatory processes 
and growth. This treatment is now called "photobiomodulation" (PBM) therapy. Despite the 
numerous studies reported, variability in irradiation settings and parameters has led to 
inconsistent outcomes. The greatest lack of knowledge is related to the effects of low 
wavelengths of blue/green light. Compared to red/NIR light, blue light is used for a limited 
range of medical applications because of its inhibitory and cytotoxic effects. However blue 
light effects have rarely been reported in adipogenesis or lipogenesis studies on adipose 
tissue. Hence, the biomodulatory potential of blue light at 453 nm wavelength was tested on 
3T3-L1 cells during and after the differentiation process with respect to 
adipogenesis/lipogenesis, metabolic processes, cell proliferation and transcriptome changes. 
PBM using blue light revealed dose dependent effects during preadipocytes 3T3-L1 
differentiation. A single irradiation performed at the first day of induction (Day0) led to a 
slight effect with a reduced lipid accumulation and changes in the expression of adipogenic 
markers that appeared down-regulated already after one exposure. Also metabolism, 
reflecting mitochondria activity, was negatively affected by blue light since oxidative 
phosphorylation and ATP contents were decreased with effects that were long lasting until 
24h. Tests with repeated irradiations for all differentiation period showed an enhanced 
inhibition in lipid accumulation and metabolism. This chronic exposure was supposed to rise 
the ROS amount leading to DNA damages that have had as consequence a cell cycle delay, 
reduced proliferation rate and cell death processes. Gene expression analysis supported this 
hypothesis by an up-regulation of the p53 pathway and for all the other genes involved in 
repair systems such as ATM, Chk1 and Claspin. The blue light spectrum, being close to the 
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harmful UVs wavelength, seems to induce cell death mediated by oxidative stress and 
damages accumulation in differentiating preadipocytes. 
On the other hand mature adipocytes treated with 21.6 j/cm
2
 or 43.2 j/cm
2
 of blue light have 
proven to be less responsive. No significant differences were reported in metabolism, growth 
and lipid storage. Similarly apoptosis has not been deregulated and no changes in ROS levels 
or cellular damages have been observed. 
 
In conclusion adipocytes seem to be more sensitive to blue light exposure during early rather 
than in late differentiation phases. Furthermore, the high doses of irradiation chosen led to 
inhibitory effects on metabolism and differentiation promoting cell death in preadipocytes 
subjected to chronic exposure while no effects were recorded in irradiated mature adipocytes. 
The results indicated that an optimal choice of irradiation parameters, particularly the dose or 
irradiation time, is important. Too high doses can lead to expected inhibitory but also 
deleterious effects on cells. Though inhibitory effects in adipogenesis or proliferation are 
requested relating to the treatment of hyperplastic obesity or dysregulation of lipid 
accumulation during childhood, the formation of aberrant cells has to be avoided. Therefore 
additional studies are needed to promote or reject blue light application in these fields. If 
tetraploid or aneuploid cells formation is not observed, blue light could be a possible 
alternative to pharmacological or surgical solutions in some obese subjects. However, there is 
currently no evidence of a possible application in hypertrophic obesity condition. 
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7 Appendix 
Table 15: complete gene expression analysis of the first set-up: irradiation during differentiation process. 
Down-regulated (Up-regulated) pathways are indicated by the negative (positive) NES coloured in green 
(red). Significant p-value and adjusted p-value (<0.05) are written in 
green.
Name
NES D1 
vs Ctrl
NES D14 
vs Ctrl
pvalue D1 
vs Ctrl
Adj. 
pvalue D1 
vs Ctrl
pvalue D14 
vs Ctrl
Adj. 
pvalue 
D14 vs Ctrl
1. Metabolism
1.0 Global and overview maps
Metabolic pathways -2.51 -2.55 0.0001 0.001302 0.000694 0.00375
Carbon metabolism -2.81 -2.93 0.00012 0.001302 0.000299 0.002066
2-Oxocarboxylic acid metabolism -2.12 -2.11 0.00017 0.001302 0.000504 0.002951
Fatty acid metabolism -2.41 -2.74 0.00014 0.001302 0.00027 0.002066
Biosynthesis of amino acids -2.42 -2.13 0.00013 0.001302 0.000281 0.002066
1.1. Carbohydrate metabolism
Glycolysis  Gluconeogenesis -2.36 -2.08 0.00014 0.001302 0.000268 0.002066
Citrate cycle (TCA cycle) -2.51 -2.75 0.00015 0.001302 0.000264 0.002066
Pentose phosphate pathway -2.13 -1.96 0.00016 0.001302 0.00104 0.005409
Pentose and glucuronate interconversions -0.95 0.89 0.52677 0.740633 0.61425 0.70111
Fructose and mannose metabolism -2.09 -1.61 0.00015 0.001302 0.020011 0.057377
Galactose metabolism -1.63 -1.06 0.01801 0.058164 0.360516 0.494171
Starch and sucrose metabolism -1.89 -1.73 0.0005 0.00341 0.01333 0.040714
Amino sugar and nucleotide sugar 
metabolism
-1.18 0.62 0.24115 0.448493 0.97321 0.984994
Inositol phosphate metabolism -1.42 -0.68 0.05245 0.143099 0.957883 0.978782
Pyruvate metabolism -2.44 -2.68 0.00015 0.001302 0.000264 0.002066
Glyoxylate and dicarboxylate metabolism -2.32 -2.5 0.00016 0.001302 0.000258 0.002066
Propanoate metabolism -2.48 -2.82 0.00016 0.001302 0.000258 0.002066
1.2. Energy metabolism
Oxidative phosphorylation -2.74 -2.97 0.00012 0.001302 0.000296 0.002066
1.3. Lipid metabolism
Fatty acid elongation -1.67 -1.79 0.012 0.040983 0.004135 0.015703
Fatty acid degradation -2.22 -2.4 0.00015 0.001302 0.000265 0.002066
Steroid biosynthesis -2.14 -2.2 0.00017 0.001302 0.000255 0.002066
Steroid hormone biosynthesis -1.38 -1.23 0.11448 0.245567 0.212864 0.337936
Glycerolipid metabolism -2.16 -2.22 0.00014 0.001302 0.000269 0.002066
Glycerophospholipid metabolism -2.08 -2.09 0.00013 0.001302 0.000281 0.002066
Ether lipid metabolism -1.46 -1.29 0.06287 0.162086 0.154626 0.264938
Arachidonic acid metabolism -1.71 -1.43 0.00918 0.032653 0.070931 0.156942
Sphingolipid metabolism 1.4 1.45 0.06219 0.161803 0.04428 0.109147
Biosynthesis of unsaturated fatty acids -1.94 -2.15 0.00016 0.001302 0.00026 0.002066
1.4. Nucleotide metabolism
Purine metabolism -1.29 1.27 0.10859 0.236533 0.097269 0.197818
Pyrimidine metabolism 0.95 1.79 0.55437 0.752552 0.000478 0.00286
1.5. Amino acid metabolism
Alanine, aspartate and glutamate metabolism -1.88 -1.62 0.00016 0.001302 0.02105 0.058565
Glycine, serine and threonine metabolism -1.76 -1.3 0.00398 0.017223 0.138273 0.245916  
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Cysteine and methionine metabolism -1.8 -1.46 0.0029 0.013293 0.048128 0.11524
Valine, leucine and isoleucine degradation -2.61 -2.96 0.00014 0.001302 0.000268 0.002066
Lysine degradation -1.83 -1.57 0.00097 0.005277 0.017069 0.050487
Arginine and proline metabolism -1.15 0.94 0.28816 0.496759 0.56254 0.672427
Tyrosine metabolism -1.74 -1.66 0.00462 0.019665 0.021533 0.059321
Tryptophan metabolism -1.91 -1.8 0.00016 0.001302 0.006753 0.024021
1.6. Metabolism of other amino acids
beta-Alanine metabolism -2.01 -1.96 0.00016 0.001302 0.001292 0.006481
Selenocompound metabolism -1.41 -0.89 0.09268 0.217025 0.603175 0.69464
Glutathione metabolism -1.76 0.93 0.00293 0.013293 0.578487 0.683004
1.7. Glycan biosynthesis and metabolism
N-Glycan biosynthesis 1.37 1.34 0.0666 0.168593 0.084359 0.178231
Other glycan degradation 1.42 0.6 0.07585 0.186973 0.952113 0.978782
Other types of O-glycan biosynthesis 1.07 0.96 0.36701 0.592692 0.526471 0.651501
Mannose type O-glycan biosynthesis 0.92 1.35 0.56871 0.757381 0.112533 0.216587
Glycosaminoglycan biosynthesis -0.38 -0.73 0.99746 0.999771 0.817998 0.867387
Glycosaminoglycan biosynthesis -0.56 -0.59 0.95544 0.999771 0.943849 0.978677
Glycosylphosphatidylinositol (GPI)-anchor 
biosynthesis
-0.56 0.96 0.97045 0.999771 0.518362 0.644512
1.8. Metabolism of cofactors and vitamins
One carbon pool by folate 0.78 1.47 0.77904 0.891746 0.049213 0.11524
Nicotinate and nicotinamide metabolism -1.47 -1.38 0.05852 0.155311 0.101691 0.20266
Folate biosynthesis -1.59 -1.5 0.02674 0.079921 0.067126 0.150899
Retinol metabolism -1.59 -1.63 0.0254 0.076759 0.027429 0.072033
Porphyrin and chlorophyll metabolism -1.75 -1.06 0.0053 0.021895 0.356681 0.491311
1.9. Metabolism of terpenoids and polyketides
Terpenoid backbone biosynthesis -2 -2.24 0.00016 0.001302 0.00026 0.002066
1.11. Xenobiotics biodegradation and metabolism
Metabolism of xenobiotics by cytochrome 
P450
-1.86 -1.5 0.00147 0.007397 0.039159 0.098247
Drug metabolism -1.7 -1.31 0.00835 0.030891 0.125924 0.230529
Drug metabolism (other enzymes) -1.36 1.41 0.08562 0.207397 0.049016 0.11524
2. Genetic Information Processing
2.1. Transcription
RNA polymerase -0.49 1.55 0.99082 0.999771 0.024178 0.065327
Basal transcription factors -0.47 1.22 0.99757 0.999771 0.175764 0.292247
Spliceosome 2.1 2.26 0.00067 0.004206 0.000147 0.002066
2.2. Translation
Aminoacyl-tRNA biosynthesis -1.27 1.41 0.14918 0.297299 0.050647 0.117618
Ribosome biogenesis in eukaryotes 0.72 1.96 0.97009 0.999771 0.000155 0.002066
Ribosome 1.77 1.78 0.00065 0.004206 0.000294 0.002066
RNA transport 1.08 2.07 0.2594 0.458429 0.000145 0.002066
mRNA surveillance pathway 0.68 1.54 0.98514 0.999771 0.009035 0.030225
2.3. Folding, sorting and degradation
RNA degradation -1 1.31 0.47084 0.700604 0.077006 0.167742
Proteasome -0.82 1.45 0.7337 0.858182 0.037946 0.096063  
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Protein export -1.68 -1.7 0.01211 0.040983 0.010957 0.035718
Ubiquitin mediated proteolysis 0.84 1.58 0.86925 0.961646 0.002353 0.010012
SNARE interactions in vesicular transport 0.7 0.92 0.92204 0.992698 0.596172 0.689401
Protein processing in endoplasmic 
reticulum
-0.53 1.04 0.99977 0.999771 0.377092 0.506999
2.4. Replication and repair
DNA replication 2.04 2.39 0.00032 0.002237 0.000161 0.002066
Base excision repair 0.87 1.58 0.67478 0.83736 0.015814 0.047274
Nucleotide excision repair 1.61 1.84 0.00862 0.031046 0.000478 0.00286
Mismatch repair 1.35 1.87 0.10491 0.235236 0.000816 0.004327
Homologous recombination 0.8 1.49 0.81171 0.918799 0.026665 0.070686
Fanconi anemia pathway 1.13 1.52 0.2426 0.448493 0.018084 0.052933
3. Environmental Information Processing
3.1. Membrane transport
ABC transporters -1.71 -1.69 0.00857 0.031046 0.011058 0.035718
3.2. Signal transduction
MAPK signaling pathway 0.93 1.1 0.72116 0.852378 0.242267 0.37405
ErbB signaling pathway -0.6 1.17 0.9863 0.999771 0.193829 0.314831
Ras signaling pathway 0.88 1.07 0.81313 0.918799 0.327807 0.456009
Rap1 signaling pathway 1.27 1.21 0.04303 0.123394 0.117519 0.223127
Calcium signaling pathway -1.14 -1.1 0.25609 0.455448 0.257034 0.392231
cGMP-PKG signaling pathway -1.5 -1.43 0.01558 0.051508 0.022442 0.061224
cAMP signaling pathway -1.12 -1.2 0.27561 0.481026 0.130036 0.232739
NF-kappa B signaling pathway 1.35 1.56 0.05097 0.140425 0.012795 0.039508
HIF-1 signaling pathway -2.14 -1.75 0.00013 0.001302 0.001734 0.007735
FoxO signaling pathway -1.3 -1.1 0.08533 0.207397 0.258288 0.392231
Phosphatidylinositol signaling system -0.95 0.95 0.55136 0.752552 0.553637 0.667692
Sphingolipid signaling pathway -0.61 0.9 0.98704 0.999771 0.656983 0.732588
Phospholipase D signaling pathway -0.69 0.89 0.94296 0.999771 0.691879 0.765425
mTOR signaling pathway -0.92 0.66 0.62627 0.79922 0.99042 0.993957
PI3K-Akt signaling pathway -1.03 -1.29 0.40317 0.629387 0.027768 0.072247
AMPK signaling pathway -2.13 -2.34 0.00012 0.001302 0.000297 0.002066
Wnt signaling pathway 1.22 1.14 0.0896 0.213822 0.215472 0.33922
Notch signaling pathway -0.53 0.46 0.98905 0.999771 0.998884 0.998884
Hedgehog signaling pathway 1.43 0.92 0.04893 0.136139 0.594212 0.689401
TGF-beta signaling pathway -0.7 -0.67 0.90857 0.991884 0.973928 0.984994
VEGF signaling pathway -0.68 1.11 0.91712 0.991884 0.294776 0.424044
Apelin signaling pathway -1.22 -1.25 0.16137 0.317098 0.098743 0.198192
Hippo signaling pathway 1.47 1.1 0.00969 0.034044 0.277199 0.405693
Hippo signaling pathway 1.79 1.24 0.0033 0.014704 0.185083 0.304142
JAK-STAT signaling pathway -0.9 0.92 0.63392 0.802395 0.618774 0.70111
TNF signaling pathway 1.55 1.65 0.00695 0.026383 0.002423 0.010012
3.3. Signaling molecules and interaction
Cytokine-cytokine receptor interaction 1.21 1.49 0.10444 0.235236 0.011712 0.037398
Neuroactive ligand-receptor interaction -0.96 -1.14 0.53614 0.749528 0.236025 0.368461
ECM-receptor interaction -1 -1.37 0.47181 0.700604 0.065408 0.148222
Cell adhesion molecules (CAMs) 1.02 1.31 0.40238 0.629387 0.091746 0.190968  
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4. Cellular Processes
4.1. Transport and catabolism
Autophagy (other) -1.36 -0.57 0.10715 0.235236 0.983879 0.990932
Mitophagy -1.27 -0.73 0.13351 0.279977 0.925853 0.963573
Autophagy -1.23 -0.76 0.13531 0.280274 0.949375 0.978782
Lysosome 1.53 0.89 0.00689 0.026383 0.699985 0.770413
Endocytosis 1.22 1.41 0.0443 0.125731 0.007299 0.025322
Phagosome 1.28 1.34 0.05568 0.150438 0.048884 0.11524
Peroxisome -2.51 -2.87 0.00013 0.001302 0.000281 0.002066
4.2. Cell growth and death
Cell cycle 1.66 2.08 0.00185 0.008966 0.000149 0.002066
Oocyte meiosis 1.3 1.65 0.04748 0.133408 0.002422 0.010012
p53 signaling pathway 1.37 1.63 0.04203 0.121768 0.005562 0.020841
Apoptosis 0.93 1.47 0.65275 0.818856 0.012261 0.038498
Apoptosis (multiple species) -0.91 0.72 0.57907 0.76345 0.884908 0.927833
Ferroptosis -1.72 -1.27 0.00481 0.020172 0.139375 0.246316
Necroptosis -0.86 1.32 0.71012 0.849127 0.057437 0.132292
Cellular senescence 1.02 1.67 0.40154 0.629387 0.000577 0.003188
Focal adhesion 1.23 1.24 0.06486 0.1657 0.091591 0.190968
Adherens junction 0.93 1.14 0.60576 0.784414 0.248993 0.382334
Tight junction 0.97 1.22 0.52671 0.740633 0.125692 0.230529
Gap junction 1.46 1.46 0.02247 0.068637 0.030284 0.078072
Signaling pathways regulating 
pluripotency of stem cells
-0.63 0.76 0.97794 0.999771 0.918972 0.959967
Regulation of actin cytoskeleton 1.41 1.54 0.00618 0.024449 0.002306 0.009971
5. Organismal Systems
5.1. Immune system
Chemokine signaling pathway 1.26 1.58 0.05859 0.155311 0.003591 0.013824
Complement and coagulation cascades -0.92 -1.26 0.56433 0.757381 0.158923 0.26902
Platelet activation 1.1 1.03 0.25023 0.450727 0.412145 0.541182
Antigen processing and presentation 1.69 1.9 0.00256 0.011978 0.000159 0.002066
Toll-like receptor signaling pathway 1.69 1.69 0.0021 0.009981 0.002483 0.01011
NOD-like receptor signaling pathway 1.77 1.97 0.00126 0.006418 0.000148 0.002066
RIG-I-like receptor signaling pathway 1.81 1.49 0.00071 0.004342 0.025183 0.067395
Cytosolic DNA-sensing pathway 1.8 2.1 0.0017 0.008367 0.000159 0.002066
C-type lectin receptor signaling pathway 1.23 1.52 0.10608 0.235236 0.01233 0.038498
Hematopoietic cell lineage -0.88 -0.99 0.63912 0.805348 0.466084 0.592622
Natural killer cell mediated cytotoxicity 1.04 1.54 0.37673 0.604921 0.015382 0.046477
IL-17 signaling pathway 1.32 1.69 0.06176 0.161803 0.0028 0.011083
Th1 and Th2 cell differentiation 0.81 1.12 0.83567 0.935547 0.273973 0.40307
Th17 cell differentiation -0.45 1.03 0.99947 0.999771 0.405481 0.534931
T cell receptor signaling pathway 1.11 1.47 0.24225 0.448493 0.020481 0.057552
B cell receptor signaling pathway 0.72 1.3 0.93696 0.999771 0.103787 0.205381
Fc epsilon RI signaling pathway 0.95 1.31 0.54716 0.752552 0.106977 0.208755
Fc gamma R-mediated phagocytosis 1.2 1.48 0.14015 0.285075 0.019931 0.057377
Leukocyte transendothelial migration 1.62 1.76 0.00629 0.024565 0.0014 0.006713  
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5.2. Endocrine system
PPAR signaling pathway -2.48 -2.98 0.00014 0.001302 0.00027 0.002066
Insulin signaling pathway -2.08 -2.11 0.00012 0.001302 0.000301 0.002066
Insulin secretion -0.89 0.83 0.62065 0.79922 0.753792 0.811554
GnRH signaling pathway 0.94 1.03 0.5913 0.772812 0.400777 0.533736
Ovarian steroidogenesis -1.3 0.81 0.16361 0.319261 0.743435 0.805747
Progesterone-mediated oocyte maturation 1.25 1.6 0.09103 0.214947 0.005881 0.02146
Estrogen signaling pathway 0.9 1.11 0.7 0.847845 0.267227 0.399419
Melanogenesis 1.23 0.96 0.12665 0.26758 0.52862 0.651501
Prolactin signaling pathway -0.83 0.88 0.72947 0.857656 0.670241 0.744418
Thyroid hormone synthesis -0.92 -0.94 0.58115 0.76345 0.541321 0.660145
Thyroid hormone signaling pathway -0.76 1.03 0.85589 0.95061 0.404249 0.534931
Adipocytokine signaling pathway -1.81 -1.94 0.00096 0.005277 0.000548 0.003141
Oxytocin signaling pathway 0.97 1.11 0.51681 0.73718 0.269693 0.400973
Glucagon signaling pathway -1.97 -2.04 0.00013 0.001302 0.000285 0.002066
Regulation of lipolysis in adipocytes -1.93 -2.11 0.00057 0.003847 0.000269 0.002066
Renin secretion -1.35 -1.1 0.09785 0.225385 0.294008 0.424044
Aldosterone synthesis and secretion -1.48 -1.27 0.02803 0.082906 0.116756 0.223127
Relaxin signaling pathway -0.77 -0.95 0.85248 0.950582 0.570881 0.676868
Cortisol synthesis and secretion -1.3 -0.97 0.13928 0.285075 0.4899 0.614538
Parathyroid hormone synthesis, secretion 
and action
0.74 0.66 0.9479 0.999771 0.974478 0.984994
5.3. Circulatory system
Cardiac muscle contraction -1.99 -2.06 0.00028 0.002024 0.000267 0.002066
Adrenergic signaling in cardiomyocytes 1.09 0.9 0.2623 0.460656 0.653011 0.73106
Vascular smooth muscle contraction -0.82 0.69 0.76312 0.885148 0.955187 0.978782
5.4. Digestive system
Salivary secretion -1.1 -1.04 0.33115 0.538459 0.379781 0.508183
Gastric acid secretion 0.98 0.95 0.47384 0.700604 0.535292 0.656843
Pancreatic secretion -1.34 -1.36 0.09999 0.228423 0.079625 0.172112
Carbohydrate digestion and absorption -1.2 -0.93 0.2476 0.450727 0.542681 0.660145
Protein digestion and absorption -0.99 -1.84 0.47621 0.700604 0.001616 0.007324
Fat digestion and absorption -2.02 -2.07 0.00017 0.001302 0.001531 0.007054
Bile secretion -1.13 1.3 0.31747 0.53419 0.12766 0.230529
Mineral absorption -1.02 1.06 0.44591 0.68098 0.3704 0.502814
Cholesterol metabolism -1.85 -2.14 0.00106 0.005638 0.000264 0.002066
5.5. Excretory system
Aldosterone-regulated sodium reabsorption -0.88 -0.92 0.6248 0.79922 0.56341 0.672427
Endocrine and other factor-regulated 
calcium reabsorption 0.87 0.89 0.67033 0.837171 0.639265 0.718534
Vasopressin-regulated water reabsorption 1.04 1.1 0.38563 0.615685 0.315418 0.443162
Collecting duct acid secretion -0.98 -0.83 0.49055 0.713526 0.701871 0.770413
5.6. Nervous system
Long-term potentiation 1.07 1.31 0.32518 0.537503 0.097793 0.197818
Synaptic vesicle cycle 0.99 1.14 0.47138 0.700604 0.259626 0.392231
Neurotrophin signaling pathway 1.05 1.2 0.32712 0.537544 0.146628 0.254719
Retrograde endocannabinoid signaling -2.14 -1.88 0.00013 0.001302 0.000579 0.003188
Glutamatergic synapse -0.86 0.77 0.68844 0.844765 0.859885 0.908374  
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Cholinergic synapse 1.13 1.07 0.21797 0.41108 0.335043 0.463778
Serotonergic synapse 1.12 1.51 0.24991 0.450727 0.020463 0.057552
GABAergic synapse 0.97 1.12 0.50185 0.721086 0.2856 0.415822
Dopaminergic synapse 0.99 1.16 0.4722 0.700604 0.204904 0.330909
Long-term depression -0.63 1.3 0.94326 0.999771 0.120534 0.227316
5.7. Sensory system
Olfactory transduction -0.98 0.94 0.49261 0.713526 0.551511 0.667692
Taste transduction 0.8 1.13 0.73602 0.858182 0.3095 0.438949
Inflammatory mediator regulation of TRP 
channels 0.85 1.27 0.77179 0.888826 0.125255 0.230529
5.8. Development
Axon guidance 1.11 -0.83 0.21438 0.407036 0.874684 0.920548
Osteoclast differentiation 0.78 1.1 0.91776 0.991884 0.295775 0.424044
5.9. Aging
Longevity regulating pathway -1.64 -1.69 0.00594 0.02383 0.002561 0.010281
Longevity regulating pathway -1.48 -1.17 0.03528 0.103271 0.206228 0.331027
5.10. Environmental adaptation
Circadian rhythm -1.63 -0.82 0.01867 0.059621 0.735362 0.800918
Circadian entrainment 1.02 1.3 0.41067 0.637557 0.106282 0.208755
Thermogenesis -2.55 -2.69 0.00011 0.001302 0.000338 0.00211
6. Human Diseases
6.1. Cancers: Overview
Pathways in cancer -0.91 0.95 0.71811 0.852378 0.616682 0.70111
Transcriptional misregulation in cancer 1.02 1.34 0.38879 0.617224 0.041242 0.102557
Viral carcinogenesis 1.11 1.55 0.19294 0.370221 0.001433 0.006713
Chemical carcinogenesis -1.65 -1.37 0.01033 0.035832 0.082629 0.1759
Proteoglycans in cancer 1.4 1.3 0.00558 0.022715 0.047133 0.114176
MicroRNAs in cancer 1.54 1.57 0.00345 0.01514 0.002196 0.00964
Central carbon metabolism in cancer -1.98 -1.42 0.00027 0.002024 0.046836 0.114176
Choline metabolism in cancer -0.96 0.85 0.52714 0.740633 0.760031 0.815147
6.2. Cancers: Specific types
Colorectal cancer -0.58 1 0.99223 0.999771 0.458346 0.585433
Renal cell carcinoma -1.15 -0.85 0.25462 0.455448 0.745531 0.805747
Pancreatic cancer 0.9 1.16 0.69746 0.847845 0.216087 0.33922
Endometrial cancer 0.95 1.34 0.55195 0.752552 0.076208 0.167301
Glioma 1.29 1.43 0.06823 0.17118 0.030614 0.078204
Prostate cancer 1.24 1.16 0.09763 0.225385 0.207334 0.331027
Thyroid cancer 0.87 1.27 0.67644 0.83736 0.144907 0.254492
Basal cell carcinoma 1.9 1.62 0.00067 0.004206 0.010206 0.033739
Melanoma 1.17 1.36 0.18331 0.355251 0.069848 0.155772
Bladder cancer 0.92 0.93 0.59974 0.780223 0.581429 0.683605
Chronic myeloid leukemia 0.72 1.22 0.9629 0.999771 0.147755 0.254719
Acute myeloid leukemia -1.25 0.8 0.15848 0.313611 0.811683 0.863951
Small cell lung cancer 0.98 1.21 0.50296 0.721086 0.15842 0.26902
Non-small cell lung cancer 0.77 1.3 0.91542 0.991884 0.097853 0.197818
Breast cancer 1.17 1.19 0.14514 0.291325 0.162394 0.273251
Hepatocellular carcinoma -0.83 1.23 0.78067 0.891746 0.097107 0.197818
Gastric cancer 1.18 1.24 0.13565 0.280274 0.108732 0.210715  
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6.3. Immune diseases
Autoimmune thyroid disease 1.34 1.31 0.11162 0.241266 0.126979 0.230529
Inflammatory bowel disease (IBD) -0.65 1.01 0.91336 0.991884 0.437632 0.564104
Systemic lupus erythematosus -0.98 1.16 0.4915 0.713526 0.238338 0.370016
Rheumatoid arthritis 1.18 1.28 0.19367 0.370221 0.121454 0.227523
Allograft rejection 1.62 1.67 0.01638 0.053509 0.007829 0.026829
Graft-versus-host disease 1.63 1.71 0.01505 0.050338 0.005852 0.02146
6.4. Neurodegenerative diseases
Alzheimer disease -2.52 -2.59 0.00012 0.001302 0.000321 0.002084
Parkinson disease -2.7 -2.83 0.00012 0.001302 0.000296 0.002066
Amyotrophic lateral sclerosis (ALS) -1.14 0.91 0.29223 0.500714 0.610629 0.700355
Huntington disease -2.56 -2.42 0.00011 0.001302 0.000326 0.002084
Prion diseases 1.17 1.42 0.24792 0.450727 0.065122 0.148222
6.5. Substance dependence
Cocaine addiction 1.37 1.11 0.08979 0.213822 0.310857 0.438949
Amphetamine addiction 1.56 1.22 0.0197 0.062213 0.183018 0.302518
Morphine addiction -0.95 0.98 0.54464 0.752552 0.490368 0.614538
Alcoholism -0.85 1.05 0.72194 0.852378 0.367678 0.501542
6.6. Cardiovascular diseases
Hypertrophic cardiomyopathy (HCM) -1.1 -1.19 0.32333 0.537503 0.18821 0.307482
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) -0.94 0.92 0.56006 0.756622 0.593112 0.689401
Dilated cardiomyopathy (DCM) -0.92 -1.01 0.58142 0.76345 0.418334 0.544476
Viral myocarditis -0.8 1.11 0.76545 0.885148 0.304729 0.434664
Fluid shear stress and atherosclerosis -1.08 1.22 0.33151 0.538459 0.127981 0.230529
6.7. Endocrine and metabolic diseases
Type II diabetes mellitus -1.42 -1.09 0.07276 0.180942 0.323654 0.452471
Insulin resistance -1.92 -2.06 0.00013 0.001302 0.000289 0.002066
Non-alcoholic fatty liver disease (NAFLD) -2.67 -2.84 0.00012 0.001302 0.000311 0.00208
AGE-RAGE signaling pathway in diabetic 
complications 0.96 1.02 0.54643 0.752552 0.424349 0.549503
Cushing syndrome -0.94 0.99 0.56702 0.757381 0.479293 0.606672
Type I diabetes mellitus 1.59 1.76 0.02143 0.06617 0.002925 0.011415
6.8. Infectious diseases: Bacterial
Bacterial invasion of epithelial cells 1.01 1.23 0.4159 0.642133 0.146968 0.254719
Salmonella infection 1.1 1.6 0.2804 0.486371 0.008894 0.03011
Pertussis 0.98 0.91 0.47554 0.700604 0.62629 0.706777
Legionellosis -1.34 -0.92 0.10643 0.235236 0.584252 0.684061
Staphylococcus aureus infection -0.83 -1.16 0.68805 0.844765 0.272913 0.40307
Tuberculosis 0.85 0.95 0.83304 0.935547 0.564743 0.672427
6.9. Infectious diseases: Viral
Hepatitis C 1.47 1.78 0.00725 0.027166 0.000298 0.002066
Hepatitis B 1.18 1.51 0.11637 0.247718 0.006973 0.024494
Measles 1.93 1.99 0.00098 0.005277 0.000153 0.002066
Human cytomegalovirus infection 1.29 1.53 0.02106 0.065761 0.001423 0.006713
Influenza A 1.84 2.11 0.00121 0.006288 0.000149 0.002066
Human papillomavirus infection 1.04 1.21 0.31345 0.530605 0.082311 0.1759  
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Human T-cell leukemia virus 1 infection 0.89 1.53 0.81417 0.918799 0.001424 0.006713
Kaposi sarcoma-associated herpesvirus infection1.15 1.6 0.14102 0.285075 0.001158 0.005917
Herpes simplex infection 1.83 1.95 0.00077 0.004592 0.000145 0.002066
Epstein-Barr virus infection 1.91 2.05 0.00081 0.00474 0.000144 0.002066
Human immunodeficiency virus 1 infection 1.62 1.99 0.00086 0.004952 0.000143 0.002066
6.10. Infectious diseases: Parasitic
Leishmaniasis -0.63 0.79 0.94678 0.999771 0.807107 0.862347
Chagas disease (American trypanosomiasis) -0.71 1.05 0.9044 0.991884 0.376631 0.506999
Malaria 1.03 -0.97 0.41968 0.644426 0.492068 0.614538
Toxoplasmosis -0.9 1.02 0.62857 0.79922 0.41853 0.544476
Amoebiasis -1.11 -1.21 0.3123 0.530605 0.165878 0.277451
6.12. Drug resistance: Antineoplastic
EGFR tyrosine kinase inhibitor resistance 0.89 0.86 0.70855 0.849127 0.725694 0.793463
Endocrine resistance 0.89 1.01 0.70506 0.849127 0.446979 0.573521
Antifolate resistance 0.85 1.7 0.69815 0.847845 0.006365 0.022931
Platinum drug resistance -1.1 1.12 0.32342 0.537503 0.264957 0.398144  
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Table 16: complete gene expression analysis of the second set-up: irradiation on mature adipocytes. 
Down-regulated (Up-regulated) pathways are indicated by the negative (positive) NES coloured in green 
(red). Significant p-value and adjusted p-value (<0.05) are written in green. 
Name
NES 
60min vs 
Ctrl
NES 
BL30min 
vs Ctrl
pvalue 
60min vs 
Ctrl
Adj. 
pvalue 
60min vs 
pvalue 
30min vs 
Ctrl
Adj. pvalue 
30min vs 
Ctrl
1. Metabolism
1.0 Global and overview maps
Metabolic pathways -1.41 -1.27 0.00017 0.004806 0.253861 0.596324
Carbon metabolism -1.56 -1.52 0.00151 0.017163 0.000212 0.004753
2-Oxocarboxylic acid metabolism -1.79 -1.76 0.00177 0.019425 0.600303 0.849276
Fatty acid metabolism -0.96 -1.03 0.51343 0.694245 0.166525 0.477788
Biosynthesis of amino acids -1.68 -1.59 0.00134 0.015953 0.493848 0.782842
1.1. Carbohydrate metabolism
Glycolysis  Gluconeogenesis -1.4 -1.11 0.03794 0.168809 0.339763 0.677
Citrate cycle (TCA cycle) -2.02 -2.05 0.00019 0.004806 0.052701 0.242521
Pentose phosphate pathway 0.9 0.91 0.62005 0.73213 0.739402 0.915308
Pentose and glucuronate interconversions -1.44 -1.22 0.04504 0.189414 0.257556 0.596324
Fructose and mannose metabolism -1.25 -0.97 0.14769 0.360978 0.293118 0.633713
Galactose metabolism -1.47 -1.06 0.03176 0.152326 0.792069 0.938861
Ascorbate and aldarate metabolism 1.29 1.44 0.13115 0.335519 0.038104 0.191303
Starch and sucrose metabolism -1.42 -1.17 0.05534 0.218055 0.000676 0.009464
Amino sugar and nucleotide sugar 
metabolism
-1.67 -1.33 0.0025 0.026506 0.785472 0.938861
Inositol phosphate metabolism -1.11 -1.77 0.249 0.477763 0.279482 0.608518
Pyruvate metabolism -1.57 -1.21 0.01232 0.085971 0.184811 0.502097
Glyoxylate and dicarboxylate metabolism -1.21 -1.01 0.18166 0.412083 0.31194 0.652147
Propanoate metabolism -1.88 -1.85 0.0002 0.004806 0.619231 0.864108
Butanoate metabolism -1.12 -1.01 0.28949 0.503922 0.244754 0.594416
1.2. Energy metabolism
Oxidative phosphorylation -1.91 -1.74 0.00019 0.004806 0.016205 0.097055
Nitrogen metabolism 0.98 0.94 0.48128 0.671603 0.396679 0.715306
1.3. Lipid metabolism
Fatty acid elongation -1.13 0.83 0.27119 0.492629 0.449576 0.746053
Fatty acid degradation -1.38 -1.12 0.05073 0.209485 0.052928 0.242521
Steroid biosynthesis 1.29 -1.12 0.14933 0.360978 0.054693 0.246657
Primary bile acid biosynthesis -0.76 -0.77 0.80245 0.832273 0.818644 0.949712
Steroid hormone biosynthesis 1.46 1.37 0.01481 0.098852 0.000739 0.009869
Glycerolipid metabolism -1.07 -1 0.32603 0.535436 0.210959 0.539703
Glycerophospholipid metabolism -1.13 -1.16 0.21237 0.444703 0.278559 0.608518
Ether lipid metabolism -0.94 0.93 0.56408 0.724575 0.011544 0.081643
Arachidonic acid metabolism -0.93 1.29 0.60681 0.73213 0.630993 0.864798
Linoleic acid metabolism -1.45 -0.97 0.03024 0.148898 0.855608 0.959394
alpha-Linolenic acid metabolism -1.57 -1.14 0.02006 0.123159 0.322923 0.665352
Sphingolipid metabolism -0.88 0.75 0.66576 0.760286 0.065857 0.27152
Biosynthesis of unsaturated fatty acids 0.83 0.84 0.73896 0.801629 0.022336 0.124674
1.4. Nucleotide metabolism
Purine metabolism 1.06 1.07 0.30753 0.519442 0.678656 0.909813
Pyrimidine metabolism 1 1.18 0.43424 0.637852 0.898616 0.959394  
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1.5. Amino acid metabolism
Arginine biosynthesis -1.16 -0.79 0.26161 0.48188 0.441643 0.736872
Alanine, aspartate and glutamate 
metabolism
-0.93 -1.08 0.56062 0.724575 0.000659 0.009464
Glycine, serine and threonine metabolism -0.67 -0.9 0.97655 0.982954 0.374366 0.702703
Cysteine and methionine metabolism -1.07 -1.13 0.32962 0.538255 0.158846 0.467489
Valine, leucine and isoleucine degradation -1.35 -1.14 0.06379 0.238819 0.568819 0.829109
Lysine degradation 0.92 0.98 0.58507 0.729892 0.071442 0.281187
Arginine and proline metabolism -1.25 1.06 0.125 0.32975 0.486786 0.782426
Histidine metabolism 1.35 1.59 0.10121 0.296259 0.26426 0.596324
Tyrosine metabolism 1.05 1.03 0.36636 0.570925 0.921672 0.960308
Phenylalanine metabolism 0.96 1 0.50206 0.691171 0.700488 0.910063
Tryptophan metabolism 1.31 1.39 0.09643 0.290244 0.091437 0.342332
1.6. Metabolism of other amino acids
beta-Alanine metabolism 1.08 1.42 0.32614 0.535436 0.156569 0.467489
Selenocompound metabolism -0.79 0.76 0.76625 0.815426 0.171908 0.488665
Glutathione metabolism 1.8 1.75 0.00063 0.009505 0.425922 0.734209
1.7. Glycan biosynthesis and metabolism
N-Glycan biosynthesis -1.29 -1.1 0.10343 0.296752 0.000843 0.010783
Other glycan degradation 1.22 1.63 0.20106 0.434682 0.423469 0.734209
Mucin type O-glycan biosynthesis 0.98 0.89 0.47248 0.66538 0.055438 0.246657
Other types of O-glycan biosynthesis -0.74 0.74 0.86493 0.88511 0.326581 0.668402
Mannose type O-glycan biosynthesis -1.08 -1.1 0.34218 0.549992 0.123494 0.416156
Glycosaminoglycan degradation 1.46 1.56 0.05118 0.209485 0.580967 0.837355
Glycosaminoglycan biosynthesis 0.84 -0.85 0.68744 0.768086 0.723556 0.914122
Glycosaminoglycan biosynthesis -0.92 -0.72 0.56383 0.724575 0.099032 0.361937
Glycosylphosphatidylinositol (GPI)-anchor 
biosynthesis
0.95 1.05 0.51695 0.694245 0.021608 0.122848
Glycosphingolipid biosynthesis -0.76 0.85 0.83873 0.864066 0.469874 0.768568
Glycosphingolipid biosynthesis 1.35 1.37 0.11527 0.315958 0.550847 0.822319
Glycosphingolipid biosynthesis 0.89 1.29 0.60913 0.73213 0.001496 0.017661
1.8. Metabolism of cofactors and vitamins
One carbon pool by folate -1.24 -1.46 0.18524 0.412083 0.000185 0.004753
Thiamine metabolism 0.88 1.11 0.62961 0.740496 0.000184 0.004753
Nicotinate and nicotinamide metabolism 1.16 1.28 0.22968 0.458216 0.000182 0.004753
Pantothenate and CoA biosynthesis -1.23 -0.91 0.19929 0.434682 0.733535 0.915308
Folate biosynthesis -0.79 0.83 0.78973 0.827465 0.00033 0.006341
Retinol metabolism 1.04 1.25 0.35658 0.563159 0.003157 0.026926
Porphyrin and chlorophyll metabolism 1.58 1.53 0.01466 0.098852 0.002336 0.022223
1.9. Metabolism of terpenoids and polyketides
Terpenoid backbone biosynthesis -0.94 -0.99 0.53678 0.704243 0.390679 0.715306
1.11. Xenobiotics biodegradation and metabolism
Metabolism of xenobiotics by cytochrome 
P450
1.9 1.87 0.00042 0.007585 0.213916 0.542747
Drug metabolism 1.91 1.89 0.00042 0.007585 0.470654 0.768568
Drug metabolism (other enzymes) 1.72 1.79 0.00063 0.009505 0.336911 0.677  
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2. Genetic Information Processing
2.1. Transcription
RNA polymerase 0.6 -0.73 0.98912 0.989117 0.00198 0.020963
Basal transcription factors -0.75 -0.76 0.90137 0.916294 0.522041 0.809907
Spliceosome 1.1 1.14 0.23275 0.458216 0.398428 0.715306
2.2. Translation
Aminoacyl-tRNA biosynthesis -1.81 -1.78 0.00135 0.015953 0.912519 0.959394
Ribosome biogenesis in eukaryotes -1.24 -1.19 0.11424 0.315958 0.018508 0.107209
Ribosome -1.33 1.26 0.03915 0.1717 0.174231 0.489467
RNA transport -1.36 -1.38 0.01948 0.122044 0.132171 0.429894
mRNA surveillance pathway 0.79 -0.7 0.92434 0.936542 0.068101 0.27152
RNA degradation -1 -1.18 0.43247 0.637852 0.009928 0.074342
2.3. Folding, sorting and degradation
Proteasome 1.09 1.32 0.28998 0.503922 0.996904 0.996904
Protein export -2.06 -2.01 0.00019 0.004806 0.147765 0.45822
Ubiquitin mediated proteolysis -0.88 -1.08 0.7834 0.824068 0.907951 0.959394
SNARE interactions in vesicular transport -1.4 -1.31 0.06096 0.23658 0.907265 0.959394
Protein processing in endoplasmic 
reticulum
-2.21 -2.07 0.00019 0.004806 0.523828 0.809907
2.4. Replication and repair
DNA replication 1.07 0.95 0.33937 0.548357 0.175379 0.489467
Base excision repair -0.87 -0.75 0.67113 0.760286 0.079488 0.305034
Nucleotide excision repair 0.66 -0.71 0.98235 0.985564 0.000213 0.004753
Mismatch repair -0.86 -0.92 0.67069 0.760286 0.033913 0.176749
Homologous recombination -0.96 -0.77 0.51786 0.694245 0.894068 0.959394
Fanconi anemia pathway 1.02 0.86 0.40871 0.612988 0.96301 0.982207
3. Environmental Information Processing
3.1. Membrane transport
ABC transporters 1.42 1.2 0.04102 0.177388 0.560996 0.828009
MAPK signaling pathway 1.25 0.96 0.0304 0.148898 0.884624 0.959394
ErbB signaling pathway 1.16 0.87 0.18207 0.412083 0.712858 0.914122
Ras signaling pathway -0.96 -0.86 0.57167 0.726472 0.571404 0.829109
Rap1 signaling pathway 1.15 0.91 0.13248 0.336128 0.753626 0.925453
Calcium signaling pathway 0.99 -1.05 0.45647 0.657924 0.92694 0.961387
cGMP-PKG signaling pathway -1.03 -1.18 0.35771 0.563159 0.702557 0.910063
cAMP signaling pathway 1.18 1.11 0.10133 0.296259 0.298926 0.638973
NF-kappa B signaling pathway 1.16 0.86 0.17174 0.397876 0.105093 0.370844
HIF-1 signaling pathway -0.99 -0.87 0.46555 0.65863 0.194644 0.519614
FoxO signaling pathway 1.38 0.98 0.02091 0.125895 0.000678 0.009464
Phosphatidylinositol signaling system -1.1 -1.74 0.2581 0.48188 0.333683 0.677
Sphingolipid signaling pathway -1.17 -1.09 0.14792 0.360978 0.788634 0.938861
Phospholipase D signaling pathway -1.18 -1.55 0.13025 0.335519 0.779204 0.938861
mTOR signaling pathway -0.93 -0.93 0.63725 0.743859 0.479374 0.774568
PI3K-Akt signaling pathway -0.97 0.96 0.53178 0.700678 0.000441 0.007398
AMPK signaling pathway -0.94 -0.88 0.59297 0.731087 0.247857 0.594416
Wnt signaling pathway 0.94 -0.82 0.60869 0.73213 0.001857 0.020361
Notch signaling pathway 0.88 1.06 0.6684 0.760286 0.00237 0.022223
Hedgehog signaling pathway 0.89 0.72 0.64883 0.751861 0.068093 0.27152  
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TGF-beta signaling pathway -0.86 -0.95 0.74934 0.807723 0.546007 0.822319
VEGF signaling pathway -1.05 -0.98 0.3552 0.563159 0.865907 0.959394
Apelin signaling pathway -1.03 -1.02 0.36892 0.572017 0.255958 0.596324
Hippo signaling pathway 0.94 0.83 0.60656 0.73213 0.100636 0.363472
Hippo signaling pathway 0.81 -0.94 0.75205 0.807723 0.059135 0.255697
JAK-STAT signaling pathway 1.57 1.54 0.00086 0.011737 0.014658 0.097055
TNF signaling pathway 1.28 1.03 0.06277 0.237891 0.263987 0.596324
3.3. Signaling molecules and interaction
Cytokine-cytokine receptor interaction 1.6 1.54 0.00022 0.004806 0.000231 0.004753
Neuroactive ligand-receptor interaction 1.47 1.41 0.00088 0.011737 0.067694 0.27152
ECM-receptor interaction -0.97 0.88 0.50559 0.692924 0.006773 0.051984
Cell adhesion molecules (CAMs) 1.17 1.32 0.12567 0.32975 0.034725 0.177675
4.1. Transport and catabolism
Autophagy (other) -1.32 -1.4 0.10306 0.296752 0.263227 0.596324
Mitophagy -1.5 -1.48 0.01582 0.103312 0.644378 0.879217
Autophagy -0.9 -1.08 0.71657 0.787263 0.572544 0.829109
Lysosome 1.1 1.27 0.23582 0.458216 0.791237 0.938861
Endocytosis -1.4 -1.35 0.00403 0.038663 0.833794 0.958707
Phagosome 1.1 1.3 0.20802 0.444703 0.898717 0.959394
Peroxisome -1.27 -1.09 0.08894 0.281794 0.695029 0.910063
4.2. Cell growth and death
Cell cycle 1.38 1.27 0.02134 0.125989 0.88891 0.959394
Oocyte meiosis -1.02 -0.95 0.40026 0.608322 0.90605 0.959394
p53 signaling pathway -0.99 0.8 0.44928 0.65681 0.524988 0.809907
Apoptosis -0.91 -0.87 0.68092 0.765722 0.243281 0.594416
Apoptosis (multiple species) 1.02 0.74 0.40932 0.612988 0.312266 0.652147
Ferroptosis -1.11 0.74 0.27868 0.497375 0.810256 0.945813
Necroptosis -1.2 -0.97 0.09828 0.292925 0.267767 0.596324
Cellular senescence 1.13 1.09 0.17237 0.397876 0.956843 0.979169
4.3. Cellular community - eukaryotes
Focal adhesion 1.06 0.96 0.28028 0.497375 0.341808 0.677
Adherens junction -1.07 -1.03 0.31778 0.527346 0.943442 0.968685
Tight junction 0.85 -1.09 0.86395 0.88511 0.551785 0.822319
Gap junction 1.22 -0.79 0.12061 0.321975 0.177427 0.489643
Signaling pathways regulating pluripotency of stem cells0.87 0.96 0.79587 0.830552 0.491093 0.782842
4.5. Cell motility
Regulation of actin cytoskeleton 0.99 -0.93 0.45563 0.657924 0.40143 0.716505
5. Organismal Systems
5.1. Immune system
Chemokine signaling pathway 1.05 1.04 0.30794 0.519442 0.966684 0.982689
Complement and coagulation cascades 1.57 1.73 0.00594 0.055223 0.898451 0.959394
Platelet activation -1 -1.05 0.43022 0.637852 0.543897 0.822319
Antigen processing and presentation 1.09 1.42 0.27825 0.497375 0.564161 0.828696
Toll-like receptor signaling pathway 1.37 1.28 0.03017 0.148898 0.71808 0.914122
NOD-like receptor signaling pathway 1.33 1.36 0.0229 0.130195 0.03174 0.170953
RIG-I-like receptor signaling pathway 1.28 1.21 0.08911 0.281794 0.375385 0.702703
Cytosolic DNA-sensing pathway 1.67 1.52 0.00313 0.030948 0.22037 0.55003
C-type lectin receptor signaling pathway 1.16 1.01 0.1567 0.374736 0.938897 0.967253  
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Hematopoietic cell lineage 1.36 1.6 0.03354 0.156005 0.537511 0.820975
Natural killer cell mediated cytotoxicity 1.23 1.2 0.09525 0.289517 0.000182 0.004753
IL-17 signaling pathway 1.15 -0.84 0.18394 0.412083 0.320118 0.664028
Th1 and Th2 cell differentiation 1.39 1.26 0.02919 0.148898 0.024248 0.132931
Th17 cell differentiation 1.39 1.17 0.02382 0.130611 0.5944 0.847777
T cell receptor signaling pathway 0.99 0.86 0.46147 0.65808 0.072975 0.283588
B cell receptor signaling pathway 1.14 1.11 0.21746 0.44563 0.016439 0.097055
Fc epsilon RI signaling pathway 1.22 0.92 0.13727 0.344102 0.147384 0.45822
Fc gamma R-mediated phagocytosis 1.24 1.04 0.10825 0.304874 0.015738 0.097055
Leukocyte transendothelial migration 1.29 1.21 0.0554 0.218055 0.408511 0.724931
Intestinal immune network for IgA 
production
1.16 1.01 0.21795 0.44563 0.00176 0.020015
5.2. Endocrine system
PPAR signaling pathway -1.29 -1.36 0.0791 0.261106 0.088552 0.335623
Renin-angiotensin system -0.91 -0.91 0.60455 0.73213 0.163374 0.473167
Insulin signaling pathway -1.06 -1.08 0.30648 0.519442 0.787269 0.938861
Insulin secretion 0.86 -0.87 0.76554 0.815426 0.247009 0.594416
GnRH signaling pathway 0.86 -0.8 0.77792 0.823522 0.609066 0.857721
Ovarian steroidogenesis 1.33 1.2 0.07641 0.257776 0.3525 0.693701
Progesterone-mediated oocyte maturation 1.27 1.2 0.07737 0.258166 0.364598 0.702703
Estrogen signaling pathway 0.97 -0.84 0.51624 0.694245 0.114589 0.399759
Melanogenesis -0.96 -0.98 0.52963 0.700678 0.432064 0.734209
Prolactin signaling pathway 0.91 -0.79 0.61106 0.73213 0.432873 0.734209
Thyroid hormone synthesis -1.14 -1.09 0.21919 0.44563 0.819784 0.949712
Thyroid hormone signaling pathway 1.18 0.83 0.13786 0.344102 0.003772 0.031242
Adipocytokine signaling pathway -0.91 -0.82 0.61566 0.73213 0.44007 0.736872
Oxytocin signaling pathway 1.23 0.82 0.07411 0.255623 0.723291 0.914122
Glucagon signaling pathway -1.29 -1.41 0.07031 0.245279 0.995702 0.996904
Regulation of lipolysis in adipocytes 1.35 1.25 0.06856 0.241945 0.146308 0.45822
Renin secretion 1.14 1.03 0.21796 0.44563 0.992262 0.996904
Aldosterone synthesis and secretion 1.04 0.81 0.36118 0.565729 0.198511 0.521128
Relaxin signaling pathway -0.88 0.83 0.76762 0.815426 0.126067 0.416156
Cortisol synthesis and secretion 1.28 1.1 0.08995 0.281794 0.531022 0.815119
Parathyroid hormone synthesis, secretion 
and action
1.14 -0.77 0.19273 0.425676 0.15989 0.467489
5.3. Circulatory system
Cardiac muscle contraction 1.15 -1.06 0.2005 0.434682 0.750927 0.925453
Adrenergic signaling in cardiomyocytes 0.99 -0.88 0.46301 0.65808 0.096793 0.358018
Vascular smooth muscle contraction -0.95 -1.08 0.57146 0.726472 0.853039 0.959394
5.4. Digestive system
Salivary secretion 1.1 0.8 0.26188 0.48188 0.36756 0.702703
Gastric acid secretion 0.93 -1.01 0.57786 0.726472 0.737905 0.915308
Pancreatic secretion 0.86 -1.13 0.79809 0.830552 0.691545 0.910063
Carbohydrate digestion and absorption 1.38 1.11 0.06165 0.23658 0.249771 0.594416
Protein digestion and absorption 0.95 -0.85 0.55882 0.724575 0.768333 0.936027
Fat digestion and absorption 0.97 1.25 0.48864 0.678791 0.921716 0.960308
Bile secretion 1.53 1.19 0.01091 0.07788 0.15881 0.467489
Vitamin digestion and absorption 1.26 1.23 0.15746 0.374736 0.133029 0.429894  
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Mineral absorption 1.48 1.09 0.02945 0.148898 0.912027 0.959394
Cholesterol metabolism -1.26 -1.13 0.11691 0.317624 0.494695 0.782842
5.5. Excretory system
Aldosterone-regulated sodium 
reabsorption
1.38 0.73 0.06668 0.240834 0.930207 0.961527
Endocrine and other factor-regulated 
calcium reabsorption
0.85 -0.98 0.73638 0.801629 0.262418 0.596324
Vasopressin-regulated water reabsorption -1.09 -0.9 0.3055 0.519442 0.866115 0.959394
Proximal tubule bicarbonate reclamation 1.15 1.03 0.26213 0.48188 0.875603 0.959394
Collecting duct acid secretion 0.89 0.89 0.61998 0.73213 0.912003 0.959394
5.6. Nervous system
Long-term potentiation 1.2 -1 0.16187 0.382254 0.016097 0.097055
Synaptic vesicle cycle 0.9 0.87 0.66471 0.760286 0.122015 0.416156
Neurotrophin signaling pathway 0.89 0.73 0.71803 0.787263 0.382439 0.711569
Retrograde endocannabinoid signaling -1.04 -1.15 0.33421 0.542867 0.900876 0.959394
Glutamatergic synapse 0.99 0.73 0.45892 0.65808 0.880999 0.959394
Cholinergic synapse -1.1 -1.12 0.24166 0.466599 0.268055 0.596324
Serotonergic synapse 0.96 1.19 0.52671 0.700003 0.974635 0.987502
GABAergic synapse -1.03 -0.96 0.37719 0.578984 0.611991 0.857906
Dopaminergic synapse -1.22 -1.14 0.09496 0.289517 0.661563 0.894713
Long-term depression 1.31 0.85 0.08389 0.271092 0.001166 0.014312
5.7. Sensory system
Olfactory transduction 1.03 1.1 0.26687 0.487678 0.36747 0.702703
Taste transduction 1.56 -0.84 0.00635 0.057305 0.698993 0.910063
Phototransduction -1.16 -1.05 0.25199 0.480505 0.00314 0.026926
Inflammatory mediator regulation of TRP 
channels
1.16 0.88 0.14905 0.360978 0.585315 0.839681
5.8. Development
Axon guidance -1.18 -1.12 0.1125 0.313977 0.922772 0.960308
Osteoclast differentiation 1.01 0.78 0.40357 0.610318 0.475853 0.772947
5.9. Aging
Longevity regulating pathway -0.85 -0.82 0.7838 0.824068 0.630532 0.864798
Longevity regulating pathway -0.75 -0.89 0.93967 0.94894 0.411122 0.72537
5.10. Environmental adaptation
Circadian rhythm 0.96 1.01 0.49815 0.688887 0.002926 0.026416
Circadian entrainment -0.92 -0.86 0.61511 0.73213 0.119489 0.41217
Thermogenesis -1.59 -1.42 0.00037 0.007572 0.859189 0.959394
6. Human Diseases
6.1. Cancers: Overview
Pathways in cancer 1.21 1.19 0.02223 0.128751 0.62684 0.864798
Transcriptional misregulation in cancer 1.22 1.17 0.07604 0.257776 0.875275 0.959394
Viral carcinogenesis 1.27 1.22 0.03742 0.168809 0.422154 0.734209
Chemical carcinogenesis 1.89 1.97 0.00021 0.004806 0.194248 0.519614
Proteoglycans in cancer 0.92 0.88 0.69493 0.770197 0.278285 0.608518
MicroRNAs in cancer 1.5 1.02 0.0011 0.01406 0.826847 0.954293
Central carbon metabolism in cancer 0.93 -0.92 0.57497 0.726472 0.135851 0.434441
Choline metabolism in cancer 1.13 0.86 0.21033 0.444703 0.159625 0.467489
6.2. Cancers: Specific types
Colorectal cancer 1.13 0.94 0.20988 0.444703 0.809846 0.945813  
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Renal cell carcinoma 1.01 1.05 0.4153 0.618919 0.010522 0.076913
Pancreatic cancer 1.13 1 0.23309 0.458216 0.441525 0.736872
Endometrial cancer 1.18 1.03 0.18282 0.412083 0.299714 0.638973
Glioma 0.9 -0.71 0.65424 0.755082 0.849817 0.959394
Prostate cancer 1.09 1.03 0.26157 0.48188 0.207623 0.539703
Thyroid cancer 0.89 0.95 0.63195 0.740496 0.657866 0.893651
Basal cell carcinoma -0.89 0.8 0.67677 0.763852 0.149491 0.458938
Melanoma 1.29 1.02 0.08068 0.263494 0.550942 0.822319
Bladder cancer 1.66 1.55 0.00804 0.063299 0.722454 0.914122
Chronic myeloid leukemia 1.12 0.93 0.23415 0.458216 0.102805 0.366992
Acute myeloid leukemia 1.58 1.65 0.00755 0.060973 0.791764 0.938861
Small cell lung cancer 1.1 0.82 0.2546 0.48188 0.732198 0.915308
Non-small cell lung cancer 1.13 0.87 0.23481 0.458216 0.000182 0.004753
Breast cancer 0.99 0.91 0.47565 0.666784 0.69281 0.910063
Hepatocellular carcinoma 1.43 1.38 0.00858 0.06588 0.005292 0.041657
Gastric cancer 0.9 0.91 0.72348 0.790422 0.052715 0.242521
6.3. Immune diseases
Asthma 0.91 1.21 0.57976 0.726472 0.040078 0.193875
Autoimmune thyroid disease 1.57 1.92 0.00734 0.060894 0.033968 0.176749
Inflammatory bowel disease (IBD) 1.29 1.55 0.09339 0.289517 0.003867 0.031242
Systemic lupus erythematosus -1.11 0.86 0.22106 0.446484 0.038634 0.191303
Rheumatoid arthritis 1.3 1.32 0.06606 0.240834 0.210002 0.539703
Allograft rejection 1.57 1.78 0.00996 0.072807 0.217127 0.546377
Graft-versus-host disease 1.57 1.85 0.00958 0.071698 0.000174 0.004753
Primary immunodeficiency 0.83 1.05 0.75247 0.807723 0.000173 0.004753
6.4. Neurodegenerative diseases
Alzheimer disease -2.11 -1.98 0.00019 0.004806 0.013434 0.091652
Parkinson disease -1.96 -1.76 0.00019 0.004806 0.040417 0.193875
Amyotrophic lateral sclerosis (ALS) 0.92 -0.88 0.58724 0.729892 0.125351 0.416156
Huntington disease -1.83 -1.73 0.00019 0.004806 0.066183 0.27152
Prion diseases -1.39 -1.03 0.0654 0.240834 0.000183 0.004753
6.5. Substance dependence
Cocaine addiction 0.96 0.96 0.50895 0.694245 0.806311 0.945813
Amphetamine addiction -0.92 -0.98 0.58971 0.730003 0.366695 0.702703
Morphine addiction 0.83 0.84 0.83836 0.864066 0.554463 0.822319
Nicotine addiction 1.28 1.6 0.11875 0.319799 0.340273 0.677
Alcoholism -1.29 -1 0.03056 0.148898 0.431211 0.734209
6.6. Cardiovascular diseases
Hypertrophic cardiomyopathy (HCM) 1.09 0.87 0.27871 0.497375 0.385177 0.712345
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC)
0.99 -1 0.45641 0.657924 0.989859 0.996904
Dilated cardiomyopathy (DCM) 1.04 0.82 0.34789 0.556263 0.371042 0.702703
Viral myocarditis 1.41 1.3 0.02752 0.148248 0.521403 0.809907
Fluid shear stress and atherosclerosis 1.39 1.56 0.01615 0.103312 0.860431 0.959394
6.7. Endocrine and metabolic diseases
Type II diabetes mellitus 0.86 -0.91 0.71783 0.787263 0.396703 0.715306
Insulin resistance -0.97 -0.91 0.52546 0.700003 0.016403 0.097055
Non-alcoholic fatty liver disease (NAFLD) -1.71 -1.6 0.00019 0.004806 0.596482 0.847777  
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AGE-RAGE signaling pathway in diabetic 
complications
1.16 1.03 0.17219 0.397876 0.002389 0.022223
Cushing syndrome 0.96 0.9 0.53922 0.70443 0.860282 0.959394
Type I diabetes mellitus 1.39 1.63 0.04368 0.186243 0.712673 0.914122
Maturity onset diabetes of the young 1.34 0.91 0.10505 0.298604 0.68245 0.910063
6.8. Infectious diseases: Bacterial
Bacterial invasion of epithelial cells -1.07 -1.07 0.31623 0.527346 0.016197 0.097055
Salmonella infection 0.89 0.82 0.6887 0.768086 0.672423 0.905412
Pertussis 1.14 1.14 0.21294 0.444703 0.62809 0.864798
Legionellosis -0.88 -0.9 0.69053 0.768086 0.768335 0.936027
Staphylococcus aureus infection 1.78 2.13 0.00021 0.004806 0.198606 0.521128
Tuberculosis 0.94 -0.92 0.61822 0.73213 0.000183 0.004753
6.9. Infectious diseases: Viral
Hepatitis C 1.62 1.46 0.00065 0.009505 0.011701 0.081643
Hepatitis B 1.35 1.29 0.0238 0.130611 0.80912 0.945813
Measles 1.45 1.32 0.00688 0.060363 0.057682 0.252976
Human cytomegalovirus infection 1.26 1.27 0.03742 0.168809 0.000374 0.00676
Influenza A 1.44 1.48 0.0073 0.060894 0.000185 0.004753
Human papillomavirus infection 1.18 1.23 0.06809 0.241945 0.369516 0.702703
Human T-cell leukemia virus 1 infection 1.14 1.1 0.12908 0.335519 0.733982 0.915308
Kaposi sarcoma-associated herpesvirus 
infection
1.24 1.1 0.05538 0.218055 0.429987 0.734209
Herpes simplex infection 1.56 1.64 0.00065 0.009505 0.84918 0.959394
Epstein-Barr virus infection 1.62 1.69 0.00022 0.004806 0.06757 0.27152
Human immunodeficiency virus 1 infection 1.27 1.35 0.03349 0.156005 0.002109 0.021578
6.10. Infectious diseases: Parasitic
Leishmaniasis 0.93 1.2 0.57536 0.726472 0.178632 0.489643
Chagas disease (American trypanosomiasis) 0.81 0.95 0.90023 0.916294 0.307779 0.651642
African trypanosomiasis 1.05 0.84 0.37188 0.573708 0.241901 0.594416
Malaria 1.07 1.29 0.31332 0.525617 0.000231 0.004753
Toxoplasmosis -0.91 0.86 0.649 0.751861 0.000458 0.007398
Amoebiasis 1.02 0.88 0.38865 0.593614 0.694843 0.910063
6.12. Drug resistance: Antineoplastic
EGFR tyrosine kinase inhibitor resistance 1.08 0.96 0.29053 0.503922 0.000232 0.004753
Endocrine resistance 1.08 1.02 0.28465 0.502232 0.395364 0.715306
Antifolate resistance 1.11 -0.72 0.29269 0.504813 0.523068 0.809907
Platinum drug resistance 1.66 1.46 0.00294 0.030098 0.470421 0.768568  
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